



**BACTERIAL DNA ARE FOUND IN LYMPH NODES OF ALL  
CHRONICALLY SYMPTOMATIC SARCOIDOSIS PATIENTS**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004065
Article Type:	Research
Date Submitted by the Author:	18-Sep-2013
Complete List of Authors:	Robinson, Lary; Moffitt Cancer Center, Thoracic Oncology Smith, Prudence; Moffitt Cancer Center, Pathology SenGupta, Dhruva; Uiversity of Washington, Laboratory Medicine Prentice, Jennifer; Uiversity of Washington, Laboratory Medicine Sandin, Ramon; Moffitt Cancer Center, Pathology
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Infectious diseases, Immunology (including allergy), Respiratory medicine
Keywords:	BACTERIOLOGY, Adult thoracic medicine < THORACIC MEDICINE, Inflammatory bowel disease < GASTROENTEROLOGY, Epidemiology < INFECTIOUS DISEASES, Thoracic medicine < INTERNAL MEDICINE, MICROBIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title: **“BACTERIAL DNA ARE FOUND IN LYMPH NODES OF ALL CHRONICALLY SYMPTOMATIC SARCOIDOSIS PATIENTS”**

Running Head: Sarcoidosis and Bacteria

Authors: Lary A. Robinson, M.D., FCCP† <lary.robinson@moffitt.org>

Prudence Smith, M.D. \* <prudence.smith@moffitt.org>

Dhruba J. SenGupta, Ph.D.‡ <dsengup@u.washington.edu>

Jennifer L. Prentice, MS, MT, (ASCP)‡ <jprentic@seattlecca.org >

Ramon L. Sandin, M.D.\* <ramon.sandin@moffitt.org>

Institutions: †Center for Infection Research in Cancer, Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, USA.

\*Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.

‡Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

Corresponding Author: Lary A. Robinson, M.D., Department of Thoracic Oncology, Moffitt

Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel: (813) 745-6895.

FAX (813) 745-3027. Email <lary.robinson@moffitt.org>

Conflict of Interest: None of the authors has any personal or financial support, nor author involvement with any organization with financial interest in the subject matter.

Research Support: This project was supported by a grant from the W. Paul Hoenle Foundation, Sarasota, Florida 34242, USA

Text Word Count: 2999 Abstract Word Count: 250

Keywords: Sarcoidosis; Atypical mycobacteria; Polymerase chain reaction; *Propionibacterium acnes*

1  
2  
3  
4  
5  
6 **ARTICLE SUMMARY:**  
7  
8  
9

10 *ARTICLE FOCUS:*  
11

- 12
- 13 • Sarcoidosis is a common yet incurable, chronic granulomatous disease of  
14 unknown etiology treated with non-specific anti-inflammatory and/or  
15 immunosuppressive drugs.  
16  
17
  - 18 • Persistently symptomatic patients worsen despite treatment with a disabling,  
19 potentially fatal clinical course.  
20
  - 21 • We propose that sarcoidosis results from a chronic granulomatous infection from  
22 a treatable pathogen in certain susceptible individuals, much like granulomatous  
23 ileitis (Crohn's disease) which shows an encouraging response to multi-drug  
24 antimicrobial therapy.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 *KEY MESSAGES:*  
37

- 38
- 39 • This case-control, retrospective study correlated clinical outcomes with the  
40 presence of detectable bacterial DNA in sarcoidosis lymph nodes versus control  
41 lymph nodes.  
42  
43
  - 44 • The entire group of sarcoidosis patients had significantly more detectable  
45 bacterial DNA than control patient lymph nodes.  
46  
47
  - 48 • However, **all** persistently symptomatic patients have detectable bacterial DNA in  
49 their lymph nodes suggesting they have more aggressive sarcoidosis that  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 potentially might benefit from antimicrobial treatment directed against a  
4  
5 presumed chronic granulomatous infection.  
6  
7  
8  
9

10  
11 *STRENGTHS AND LIMITATIONS:*  
12

- 13 • Although a number of prior studies have demonstrated the consistent presence of  
14 bacterial DNA (mostly atypical mycobacteria and *Propionibacterium acnes*) in  
15 sarcoidosis tissue, the current study is the first to correlate clinical outcomes with  
16 the presence of detectable bacterial DNA, suggesting the most promising  
17 candidates for treatment.  
18  
19
- 20 • Nevertheless, the molecular approach to bacterial detection has distinct limitations  
21 including possible false-positive results secondary to contaminated PCR reagents,  
22 the paraffin imbedding process, or post-embedding handling and processing of the  
23 paraffin block.  
24  
25
- 26 • Additionally, the number of lymph nodes positive for bacterial DNA may be  
27 significantly underestimated because of the tendency of the formalin-fixation and  
28 paraffin embedding process to breakdown prokaryotic DNA.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**INTRODUCTION:** Sarcoidosis is an incurable, chronic granulomatous disease primarily involving the lungs and lymph nodes of unknown etiology, treated with non-specific anti-inflammatory/immunosuppressive drugs. Persistently symptomatic patients worsen with a disabling, potentially fatal clinical course. To determine a possible infectious cause, we correlated in a case control study clinical information with the presence of bacterial DNA in sarcoidosis mediastinal lymph nodes compared to control lymph nodes resected during cancer surgery.

**METHODS:** We retrospectively studied formalin-fixed, paraffin-embedded, mediastinal lymph nodes from 30 sarcoidosis patients and 30 control lung cancer patients. Nucleic acids were extracted from nodes, were evaluated by rRNA PCR for bacterial 16S rDNA, and the result was sequenced and compared to a bacterial sequence library. Clinical information was correlated.

**RESULTS:** 11/30 (36.7%) of lymph nodes from sarcoidosis patients had detectable bacterial DNA, significantly more than control patient lymph nodes (2/30, 6.7%),  $p = 0.00516$ . At presentation, 19/30 (63.3%) sarcoidosis patients were symptomatic including all patients with detectable bacterial DNA. Radiographically, there were 18 Stage I and 12 Stage II patients. All Stage II patients were symptomatic and 75% had PCR-detectable bacteria. After a mean follow-up of  $52.8 \pm 32.8$  months, **all** patients with PCR-detectable bacteria were persistently symptomatic requiring treatment.

**DISCUSSION:** 36.6% of sarcoidosis patients had detectable bacteria DNA on presentation, **all** were quite symptomatic, and most were radiographically-advanced stage II patients. These findings suggest bacterial DNA-positive, symptomatic patients have more aggressive

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

sarcoidosis that persists long term, and might benefit from antimicrobial treatment directed against this presumed chronic granulomatous infection.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-004065 on 23 December 2013. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

## INTRODUCTION

Sarcoidosis is a multisystem, granulomatous disease whose etiology is obscure and controversial. Nevertheless, the condition is relatively common with a significantly higher age-adjusted annual incidence in African-Americans (35.5 cases per 100,000) versus Caucasian-Americans (10.9 cases per 100,000). An estimated one million people in the U. S. have this disease. Based on the current U.S. population of 315,556,000, there will be approximately 38,605 new cases of sarcoidosis this year and just over 1000 (2.6%) will die of the illness.<sup>1,2</sup>

The fundamental pathologic abnormality in the disease is the formation of non-caseating epithelioid granulomas, which usually confine poorly soluble foreign material that simply cannot be removed by a single phagocytic cell. The key feature in sarcoidosis is activated CD4+ T cells which differentiate into type 1 helper T cells (Th1), secreting interleukin-2 and interferon- $\gamma$ , augmenting macrophage TNF- $\alpha$ , and amplifying the local cellular immune response.<sup>3,4</sup> This granulomatous inflammation interferes with local tissue homeostasis leading to organ impairment.

Since sarcoidosis primarily involves the lungs, eyes and skin, attention has focused on airborne environmental antigens that might trigger this presumed hypersensitivity response with its T cell-mediated cellular immune response.<sup>3</sup> Similar granulomatous responses can be seen from a variety of infectious agents including mycobacteria, parasites (schistosoma), and fungi (coccidiomycosis). Early studies reported associations with non-infective agents including beryllium, zirconium, aluminum, wood-burning stoves, tree pollen, clay soil, talc, insecticides, inorganic particles, and moldy environments, but none of these theoretical causes has endured.<sup>3,5,6</sup> There is also a several-fold increased incidence of sarcoidosis occurring in siblings

1  
2  
3 and parents, as well as a consistent strong association with specific gene products such as class I  
4 and class II HLA antigens, which may add to the familial connection.  
5  
6

7  
8 Although no infectious agent has been cultured directly from sarcoidosis tissues, clinical  
9 and immunologic characteristics of the disorder provide the strongest support for a microbial  
10 etiology, at least in some patients.<sup>5-7</sup> To explore a possible infectious cause in patients seen at the  
11 Moffitt Cancer Center, we correlated the clinical presentation and long-term follow-up of  
12 sarcoidosis patients with the presence of bacterial DNA in archived, surgically-resected  
13 mediastinal lymph nodes. Results from sarcoidosis nodes were compared to control lymph nodes  
14 resected at the time of lung surgery in node-negative, Stage I non-small cell lung cancer patients.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 27 **METHODS**

### 28 29 *Regulatory Oversight*

30  
31 Tissue and clinical data in this case-control study was obtained after approval by the  
32 Moffitt Cancer Center Scientific Review Committee Protocol MCC #16131 and the University  
33 of South Florida IRB Protocol #108656.  
34  
35  
36  
37  
38  
39

### 40 41 *Study Design*

42  
43 By searching the Moffitt Cancer Center surgical pathology database between January 1,  
44 2000 and April 1, 2010, we retrospectively identified 30 randomly-chosen patients who were  
45 diagnosed with sarcoidosis based on the typical radiographic and clinical presentation, and the  
46 histologic finding of non-caseating epithelioid granulomata in lymph nodes obtained sterilely  
47 only by mediastinoscopy, to avoid possible microorganism contamination by endoscopic  
48 biopsies. Special stains for microorganisms were negative on the specimens. For inclusion in  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 this group, the following criteria were used to make the diagnosis of sarcoidosis: 1) chest  
4 radiograph and chest CT findings of symmetrical mediastinal and hilar adenopathy with or  
5 without reticulonodular infiltrates in the lung fields (see Figure 1); 2) when performed, PET  
6 scans demonstrated glucose avidity in the enlarged lymph nodes (see Figure 2); 3) asymptomatic  
7 presentation or typical symptoms of dyspnea, cough, chest tightness/pain, night sweats, fevers,  
8 fatigue, malaise, skin rash or weight loss; 4) lymph nodes showing histologic features of  
9 confluent, non-caseating granulomata; and 5) any known microorganism causes of granulomata  
10 were excluded by history or culture. All histopathologic specimens were reviewed by one of us  
11 (P.S.) to reconfirm the diagnosis made originally by departmental pathologists at Moffitt.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 To insure sterile collection, all control specimens were taken from lymph nodes removed  
26 at open thoracotomy by one of us (L.R.) in 30 (1:1 match with cases) randomly-chosen patients  
27 with Stage IA non-small lung cancer. Lymph nodes were selected only from patients with small  
28 peripheral tumors, no obstructive atelectasis, and no evidence of active infection. One of us (P.S.)  
29 reviewed all control lymph node histology to verify there were no metastases, acute  
30 inflammation, or granulomata.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 *Clinical Data*

42  
43 Clinical data on the patient demographics, initial presenting symptoms and objective  
44 findings were extracted from the electronic medical record on all sarcoidosis patients by one of  
45 us (L.R.). Patients were staged using the modified Scadding radiographic staging system: stage 0  
46 normal chest x-ray; stage 1 hilar and mediastinal adenopathy alone; stage 2 adenopathy and  
47 pulmonary infiltrates; stage 3 pulmonary infiltrates alone; and stage 4 pulmonary fibrosis.<sup>4</sup> Long-  
48 term follow-up clinical status and subsequent treatment regimens for all sarcoidosis patients were  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 obtained from the electronic medical record and telephone calls placed to the patients or their  
4  
5 immediate family.  
6  
7  
8  
9

### 10 *DNA Extraction*

11  
12 De-identified, formalin-fixed, paraffin-embedded blocks of lymph nodes from sarcoidosis  
13 and control patients were sent to the Departments of Laboratory Medicine and Microbiology at  
14 the University of Washington (Seattle, WA), where investigators were blinded as to the identity  
15 of the specimens. The DNA extraction from paraffin-embedded blocks was performed after  
16 paraffin was removed by incubation in xylene.<sup>8</sup>  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 *PCR Analysis for 16S ribosomal DNA, Heat Shock Protein 65(hsp65), RNA polymerase subunit* 28 29 *(rpoB)*

30  
31 The 16S gene fragment was amplified as previously described.<sup>8</sup> The hsp65 gene was  
32 amplified using TB11 and TB12 primers, and the RNA polymerase subunit gene (rpoB) was  
33 amplified using MF and MR primers.<sup>9</sup> The amplified products were then sequenced using the  
34 Big Dye Sequencing kit (Applied Biosystems, Foster City, CA) using the vendor's recommended  
35 protocol. The sequences of two strands were assembled into doubled-stranded contig using  
36 Sequencher software (Gene Codes, Ann Arbor, MI). The final sequences were used to search the  
37 National Center for Biotechnology Information (National Institutes of Health) database using  
38 BLAST (Basic Local Alignment Search Tool) to identify the amplified DNA.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Quantitative Variables*

The primary variable to be compared between the sarcoidosis and controls patients is the number of patients in each group with bacterial DNA found in lymph nodes. The N-1 Two Proportion test for comparing independent proportions for small sample sizes is used to compare the results between the two groups.<sup>10</sup> All numerical data is expressed as the mean  $\pm$  standard deviation.

## **RESULTS**

Demographic and clinical characteristics of the 30 sarcoidosis study patients are found in Table 1.

### *Demographics*

Patient ages are: mean  $52.5 \pm 12.3$  years (median 53 years, range 30-75 years). The male:female ratio is 14:16. The ethnicity: Caucasian 73.3% (22), African-American 16.7% (5), and Hispanic 10% (3). Most patients were overweight: mean BMI  $31.4 \pm 6.9$ , median 28.5, range 18.8-47.3.

### *Clinical Presentation*

At the time of initial presentation, 19 of 30 patients (63.3%) were symptomatic, usually with multiple symptoms. Of these 19 patients, the duration of symptoms before diagnosis was a mean  $22.1 \pm 30.0$  months (median 12 months, range 1-120 months). The most common symptoms were night sweats 9 (30.0%); dyspnea 8 (26.7%); chest pain 7 (23.3%); chest tightness 5 (16.7%); fevers 3 (10.0%); fatigue 3 (10%); skin rash 2 (6.7%); and stomach ulcer 2 (6.7%). Other symptoms present in at least one patient include: dyspepsia, dysphagia, diarrhea,

Table 1. Sarcoidosis Patient Results

No.	Age/ Sex	Race	X-ray Stage	Pack-Year Smoking	Prior Cancer	Chemo	PCR Result on Lymph Nodes	Initial Symptoms (year)	Follow- up (mo.)	Current Status (Long-Term)
1	41/F	AA	I	7	Uterine	No	<i>Mycobacteria chelonae</i>	Yes (2009)	36	Sympt., alive
2	63/F	C	II	20	Breast	Yes	<i>Mycobacteria chelonae</i>	Yes (2008)	12	Sympt., deceased from COPD 2009
3	64/F	C	II	None	None	No	<i>Mycobacteria mucogenicum</i>	Yes (2008)	41	Sympt., alive
4	43/M	C	I	None	Melanoma	No	Negative	No (2009)	31	Asympt., alive
5	61/F	C	I	None	Synovial cell sarcoma	Yes	Negative	No (2009)	23	Asympt.; new endomet. ca, alive
6	39/M	C	II	5	None	No	<i>Propionobacterium acnes</i>	Yes (2008)	35	Sympt., alive
7	58/M	C	I	3	Tonsil cancer	Yes	<i>Corynebacterium propinquum</i>	Yes (2006)	65	Sympt.; tonsil ca. relapse, alive
8	54/M	C	II	None	None	No	<i>Propionobacterium acnes</i>	Yes (2006)	60	Sympt., alive
9	52/F	AA	I	6	None	No	Negative	Yes (2007)	58	Sympt., alive
10	53/F	C	I	5	Melanoma	Yes	Negative	No (2007)	53	Asympt., alive
11	34/M	AA	II	None	None	No	<i>Propionobacterium acnes</i>	Yes (2007)	53	Sympt., alive
12	40/M	C	I	Cigars	None	No	Negative	Yes (2007)	36	Sympt., alive
13	49/M	AA	II	None	None	No	<i>Duganella zoogloeoides</i>	Yes (2010)	Lost	Unknown, alive
14	57/F	AA	II	5	Breast	Yes	<i>Propionobacterium acnes</i>	Yes (2000)	136	Sympt; breast ca. relapse; polymyalgia rheumatica; Hashimoto's thyroiditis, alive
15	67/M	C	I	None	None	No	Negative	No (2001)	Lost	Unknown, alive
16	30/M	H	I	None	None	No	Negative	No (2001)	Lost	Unknown, alive
17	75/F	C	I	None	Ovarian	Yes	Negative	No (2002)	36	Asymptomatic, deceased from ca., 2005
18	67/F	C	I	50	Liposarcoma	No	Negative	No (2003)	106	Sympt., alive
19	60/F	C	I	None	Nerve sheath tumor	No	Negative	No (2003)	60	Asympt., deceased unknown cause 2008
20	41/F	C	I	None	None	No	Negative	No (2005)	78	Asympt., alive
21	50/F	C	I	None	None	No	Negative	Yes (2005)	73	Asympt., alive
22	48/F	C	I	None	Breast	Yes	<i>Propionobacterium acnes</i>	Yes (2003)	24	Sympt.; deceased from ca. 2005
23	41/F	C	II	None	Adrenal ca; melanoma	Yes	Negative	Yes (2006)	4	Deceased from ca. 2007
24	35/M	H	I	2.5	None	No	Negative	Yes (2006)	24	Asympt., alive
25	32/M	C	I	1.0	None	No	Negative	No (2006)	Lost	Unknown, alive
26	37/M	C	II	15	Hodgkin's disease	Yes	<i>Propionobacterium acnes</i>	Yes (2007)	66	Sympt., alive
27	51/F	AA	II	None	None	No	Negative	No (2007)	64	Sympt; (mildly), alive
28	56/F	C	II	None	Colon ca.	Yes	Negative	No (2008)	Lost	Unknown, alive
29	33/M	C	I	5	Melanoma	No	Negative	No (2009)	38	Asympt., alive
30	52/F	H	II	1	Uterine	No	Negative	Yes (2002)	48	Asympt., alive

1  
2  
3  
4  
5  
6  
7 Table 1 abbreviations: AA = African-American; Asympt. = asymptomatic; C = Caucasian; Ca. = cancer;  
8 Chemo = chemotherapy; COPD = chronic obstructive pulmonary disease; H = Hispanic; Sympt. =  
9 symptomatic. All patients positive on PCR for microorganism DNA in lymph nodes are shown in bold  
10 type.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 constipation, kidney stones, joint and muscle pains, orthopnea, nose and mouth skin lesions,  
4  
5 intermittent bronchospasm, malaise, and weight loss.  
6  
7

8 Co-morbidities: asthma 2 (6.7%); coronary artery disease 2 (6.7%); diabetes mellitus 4  
9  
10 (13.3%); hypertension 5 (16.6), and one each of gout, hypothyroidism, eczema, fibromyalgia,  
11  
12 and Crohn's disease. Malignancies were extremely common with over half (53.3%) having a  
13  
14 current or prior tumor. The malignancies prior to or at the time of presentation are: breast 3,  
15  
16 melanoma 3, uterine 2, sarcomas 3, tonsil 1, ovary 1, adrenal 1, colon 1, and Hodgkin's  
17  
18 lymphoma 1.  
19  
20  
21  
22  
23

### 24 *Radiographic Studies*

25  
26 Chest CT was performed on all 30 patients and all had symmetrical mediastinal and hilar  
27  
28 adenopathy. Four of 30 (13.3%) had obvious abdominal adenopathy. Lung nodules were present  
29  
30 in 12 patients (40.0%) and were radiographic Stage II sarcoidosis. The other 18 patients (60.0%)  
31  
32 had Stage I disease. All 12 Stage II patients were symptomatic. PET/CT scans were done in 25  
33  
34 of 30 sarcoidosis patients. All demonstrated glucose avidity in the enlarged mediastinal and hilar  
35  
36 nodes (see Figure 2 for typical example), and glucose avidity was seen in the abnormal  
37  
38 abdominal nodes in the 4 patients with radiographic adenopathy below the diaphragm.  
39  
40  
41  
42  
43  
44  
45

### 46 *Laboratory Results*

47  
48 Twelve of 30 patients had lymph node tissue sent at the time of mediastinoscopy for  
49  
50 aerobic, fungal and mycobacterial cultures. All cultures showed no growth after six weeks  
51  
52 incubation.  
53  
54  
55  
56  
57  
58  
59  
60

### *Bacterial DNA Detected by PCR*

Eleven of 30 lymph nodes (36.7%) in sarcoidosis patients had bacterial DNA present by PCR. Only 2 of 30 (6.7%) control patients were found to have bacterial DNA in their lymph nodes. The microorganisms present in each group are shown in Table 2. There are significantly more sarcoidosis patient lymph nodes positive for microorganism DNA than control lymph nodes: 11/30 versus 2/30,  $p = 0.00516$  (2-tailed  $p$ -value).

All sarcoidosis patients with detectable bacterial DNA in lymph nodes (36.7%) were symptomatic at presentation. Additionally, 73% (8/11) of bacterial DNA-positive sarcoidosis patients were both symptomatic at presentation and had radiographic Stage II disease.

### *Long-Term Follow-up*

Long-term follow-up was complete in 25 of 30 (83.3%) of sarcoidosis patients, for a mean follow-up of  $50.4 \pm 28.2$  months (median 48 months, range 4 -132 months). Five of these patients are deceased: 3 from cancers, 1 from chronic obstructive pulmonary disease, and one from unknown causes. The other five patients lost to direct follow-up are still living based on information obtained from the Social Security Death Index.<sup>11</sup>

Of the 10 sarcoidosis patients with bacterial DNA found in their lymph nodes in whom long-term follow-up was available, **all** were symptomatic at follow-up a mean  $52.8 \pm 32.4$  months (median 47 months, range 12-136 months). The one additional bacterial DNA-positive patient was lost to follow-up.

**Table 2. Bacterial DNA detected by PCR****Sarcoidosis (11/30)***Propionibacterium acnes*: 7*Mycobacterium**chelonae*: 2*mucogenicum*: 1*Duganella zoolooides*: 1*Corynebacterium propinquum*: 1**Control (2/30)***Mycobacterium avium*: 1*Propionibacterium acnes*: 1



## DISCUSSION

The objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial DNA by molecular methods and b) correlate the results with clinical characteristics of the patients.

### *Bacterial DNA*

As expected, our molecular testing using PCR demonstrated that over one-third of sarcoidosis patients (36.7%) had evidence of bacterial DNA in the nodes, indicating either past or current involvement with these microorganisms. This percentage of bacterial DNA-positive specimens falls in the range found in numerous prior published studies from the last two decades (using various methodologies), which range from 26%-80% positive (Table 3<sup>5,7,12-15</sup>).

Furthermore, atypical mycobacteria and *Propionibacterium acnes* represented almost all DNA identified, also consistent with the findings of the multiple prior studies (Table 3). Additionally identified were one skin and mucous membrane organism (*Corynebacterium propinquum*), and one aerobic Gram negative bacillus (*Duganella zoogloeooides*) that is usually found in aqueous environments. Interestingly, the latter patient (no. 13) with *Duganella zoogloeooides* was an asbestos technician originally from tropical Haiti. As a disclaimer, just the finding of DNA from a microorganism in lymph nodes does not tell us whether the viable organism is present nor whether it caused the granulomatous reaction.

Similar to prior published studies summarized in Table 3, significantly less (only 2 of 30 or 6.7%,  $p = 0.00516$ ) of control lymph nodes resected at the time of lung cancer surgery showed evidence of bacterial DNA (*Mycobacterium avium intracellulare* and *Propionibacterium acnes*).

This difference strongly suggests that the demonstration of bacterial DNA in sarcoidosis lymph

Table 3. Selected studies of DNA of infectious agents found in sarcoidosis tissues

Author/Year	Sarcoid Tissue (No. patients)	Technique	Organisms (%)	Control No. (% organisms)
Li, 1999 <sup>11</sup>	Skin (20)	PCR (restriction enzyme pattern)	<i>Mycobacteria</i> (2 <i>tuberculosis</i> , 14 other <i>mycobacteria</i> . 80% total positive)	20 Normals (0% organisms)
Du Bois, 2003 <sup>7</sup> (Review of pre-1999 studies)	Lymph nodes (12 studies with 295 patients)	PCR (various methods)	<i>Mycobacterium</i> sp. (34%)	Various
Eishi, 2002 <sup>12</sup> (5 center study)	Lymph nodes (108)	Quantitative real-time PCR	<i>P. acnes</i> (72%) <i>P. granulosum</i> (55%) <i>M. tuberculosis</i> (4%) <i>E. coli</i> (2%)	86 Normals (29% <i>P. acnes</i> , 12% <i>P. granulosum</i> , 2% <i>M. tuberculosis</i> )
Drake, 2002 <sup>13</sup>	Lymph nodes (25)	Nested PCR	<i>Mycobacterium</i> sp. (60%)	25 Normals (0%)
Gupta, 2007 <sup>5</sup> (metanalysis)	Various (31 studies with 874 patients)	PCR (various methods)	<i>Mycobacterium</i> sp. (26%)	745 Controls (3%)
Ichikama, 2008 <sup>14</sup>	Bronchoalveolar lavage (42)	Quantitative PCR	<i>Propionibacterium</i> sp. (3X higher genome levels vs. controls)	30 Controls (low levels same genome)

1  
2  
3 nodes is a real finding in our study (and in over 35 prior published studies) and they are not just  
4  
5 processing contaminants, therefore pointing to microorganisms as potential contributors to the  
6  
7 genesis of this disease. In addition, *Propionibacterium acnes* DNA was found in only 1 of 30  
8  
9 (3.3%) control lymph nodes in our study, in stark contrast to Ishige and associates in Japan who  
10  
11 reported this microorganism is an ubiquitous pulmonary lymph node commensal found in 8 of 11  
12  
13 (72.7%) non-sarcoid patients in their study.<sup>16</sup> Such a very high positive result in their study is  
14  
15 likely due to either geographical/ethnic/racial differences or potential contamination in processing.  
16  
17  
18  
19  
20

### 21 22 *Clinical Characteristics*

23  
24 Perhaps the most intriguing findings came from correlation of the PCR findings with the  
25  
26 clinical information. All patients with lymph nodes containing bacteria DNA on presentation  
27  
28 were also highly symptomatic and 75% of them had the poorer-prognosis radiographic stage II  
29  
30 findings. Moreover, after a median 4 years follow-up, all bacterial DNA-positive patients were  
31  
32 *still* highly symptomatic. This striking correlation strongly suggests that demonstration of  
33  
34 bacterial DNA by PCR in lymph nodes on initial presentation is an adverse prognostic factor and  
35  
36 makes it unlikely that these patients will have a spontaneous remission.  
37  
38  
39  
40

41  
42 Indeed, if infection with one of these microorganisms triggers an exuberant  
43  
44 granulomatous immune response, the 50-80% of patients who usually have a spontaneous  
45  
46 remission<sup>1</sup> likely clear the offending organism and the immune reaction subsides. We postulate  
47  
48 that those patients who have persisting symptomatic disease, likely continue to harbor the  
49  
50 microorganism which perpetuates the vigorous, destructive immune response, and as well as  
51  
52 permit the microorganism to travel elsewhere to other organs to create distant granulomatous  
53  
54 inflammation.  
55  
56  
57  
58  
59  
60

### Limitations of Study

Many pathogenic microorganisms such as *Tropheryma whippelii* (Whipple's disease) or coronaviruses (severe acute respiratory syndrome) cannot be grown directly in culture or they are very slow growing or fastidious such as *Mycobacterium leprae* (leprosy).<sup>5</sup> In these instances, detection and identification rely on molecular mechanisms such PCR used in this study. Nevertheless, the molecular approach has distinct limitations including possible false-positive results secondary to contaminated PCR reagents, the paraffin imbedding process, or post-embedding handling and processing of the paraffin block. However in our study, thirty control lymph nodes were processed in an identical manner and bacterial DNA was detected in only 2/30 (6.6%), significantly less than the sarcoidosis nodes (36.7%,  $p = 0.00516$ ), suggesting that contamination is unlikely to account for the findings.

Additionally, the number of lymph nodes positive for bacterial DNA may be significantly underestimated because of the tendency of the formalin-fixation and paraffin embedding process to breakdown prokaryotic DNA. Also, over time other investigators have found degradation of the prokaryotic bacteria DNA (especially mycobacteria) with aging of the paraffin-embedded specimens.<sup>14</sup> Of note, the only 3 sarcoidosis lymph nodes positive for mycobacteria in our study were less than 3 years old when evaluated by PCR. Had we used fresh lymph node tissue like Drake and associates<sup>14</sup> who found 60% PCR positive for mycobacteria species, there may have been a much higher rate of positive bacterial DNA results (particularly mycobacteria) in our study.

### *Implications of the Study*

Sarcoidosis is a granulomatous disease primarily involving the lungs, lymph nodes and other organs that appears to be the result of an exuberant T cell and macrophage immunologic response to the continued presentation of a poorly degradable antigen. Numerous non-infective agents have been implicated based on epidemiologic basis but none have stood up to scrutiny.<sup>1,3,5</sup> The focus over the last two decades has been on infective agents that might trigger sarcoidosis, with the strongest suspects found in the mycobacteria family and the common commensal *Propionibacterium acnes*. And like classical tuberculosis where up to 90% of people infected with *Mycobacterium tuberculosis* remain in remission without treatment,<sup>17</sup> sarcoidosis also has a 65-80% spontaneous remission rate without treatment.<sup>1</sup> One may speculate that similar to tuberculosis, the immune system, after its initial response to a triggering microorganism, is successful in eradicating the agent and the immune response subsides. Then in the 20% or so with persistent and progressive sarcoidosis, the organism remains viable and perpetuates the destructive immune response.

Symptomatic sarcoidosis is usually treated with various anti-inflammatory and immunosuppressive agents such as corticosteroids, methotrexate and TNF-inhibitors (biologics).<sup>18</sup> The similarities in immunologic abnormalities and treatment to another debilitating granulomatous disease, Crohn's disease, are striking.<sup>19</sup> Granulomatous ileitis (Crohn's) has been suspected by many investigators to be the result of a chronic infection with the obligate intracellular microorganism *Mycobacterium avian* subspecies *paratuberculosis* (MAP), that is known to cause a granulomatous ileitis in cattle and other ruminants called Johne's disease.<sup>20</sup> Although the classical treatment of Crohn's disease has been with immunosuppressive agents just like sarcoidosis, many recent studies suggest a much more effective treatment with less side

1  
2  
3 effects may be a triple antibiotic regimen geared toward the putative triggering agent MAP.<sup>21-23</sup>  
4  
5 In fact, many in the field suspect that this intracellular organism (MAP) that resides in the  
6  
7 macrophage impairs the normal autophagy that would usually eradicate the organism.<sup>21</sup> Agents  
8  
9 that enhance autophagy such as 16 $\alpha$ -bromoepiandrosterone,<sup>24,25</sup> currently in human trials, may  
10  
11 prove effective along with antibiotics in Crohn's disease.<sup>21</sup>  
12  
13

14  
15 Can some antibacterial/anti-mycobacterial regimen such as that used in Crohn's disease  
16  
17 alter the natural history of sarcoidosis in chronically symptomatic patients? Sixty years ago a  
18  
19 number of small trials using classical anti-tuberculous drugs (isoniazide, streptomycin, or  
20  
21 cortisone) were published with discouraging results.<sup>26</sup> However, atypical mycobacteria (rather  
22  
23 than *M. tuberculosis*) that are more likely to be one of the etiologic agents in sarcoidosis, are  
24  
25 almost all resistant to the standard anti-tuberculosis agents such as isoniazid.<sup>27-32</sup> And if other  
26  
27 organisms such as *Propionibacterium acnes* or perhaps cell-wall deficient (L-forms) bacteria  
28  
29 trigger and perpetuate sarcoidosis in some individuals, then the standard anti-tuberculous drugs  
30  
31 would also be ineffective.  
32  
33  
34  
35

36  
37 The tetracycline derivatives (minocycline and doxycycline), as well as the anti-malarial  
38  
39 drug chloroquine have been shown to be quite effective in treating cutaneous sarcoidosis.<sup>33</sup>  
40  
41 Minocycline can produce complete responses in up two-thirds of cases, although it is debated  
42  
43 whether this is an anti-microbial effect or an immunomodulating effect.  
44  
45  
46  
47  
48  
49  
50

### 51 *Conclusions*

52  
53 Over the last three decades or more, numerous studies have examined every aspect of  
54  
55 sarcoidosis including its dysfunctional immune response. The primary therapy is immune  
56  
57  
58  
59  
60

1  
2  
3 suppression in various forms but this treats only symptoms and does not seem to alter the natural  
4 history of the disease.<sup>4,18</sup> Dozens of studies (Table 3) have repeatedly demonstrated evidence of  
5 microorganisms in 30-80% of sarcoidosis tissues, mostly various mycobacteria and  
6  
7  
8  
9  
10  
11 *Propionibacterium acnes*, and more of these molecular studies is not likely warranted.

12  
13 Perhaps we should follow the lead of the Crohn's disease gastroenterologists<sup>21,22</sup> and  
14 proceed with a therapeutic clinical trial using a regimen of multiple antibiotics in persistently-  
15 symptomatic, advanced stage sarcoidosis patients. Indeed, if there is a persistent, viable  
16 microorganism infection causing the continuing or progressive debilitating symptoms and organ  
17 failure, antibiotics might favorably impact the course of this disease.  
18  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **FIGURE LEGENDS**

28  
29 **Figure 1.** Contrast-enhanced computed chest tomography at 2 different axial levels showing  
30 typical symmetrical hilar and mediastinal adenopathy.  
31  
32

33  
34 **Figure 2.** PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph  
35 nodes (arrows).  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **ACKNOWLEDGEMENTS**

45  
46  
47  
48 **Author contributorship:** Dr. Robinson had full access to all of the data in the study and takes  
49 full responsibility for the integrity of the data and the accuracy of the data analysis.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *Dr. Robinson:* Contributed to the conception, hypotheses delineation and design of the study;  
4 data acquisition, analysis and interpretation; and writing and revision of the article prior to  
5 submission.  
6  
7  
8

9  
10 *Dr. Smith:* Contributed to the conception, hypothesis delineation, and design of the study; data  
11 acquisition, analysis and interpretation; and revision of the article prior to publication.  
12  
13

14 *Dr. SenGupta:* Contributed to the data acquisition, analysis and interpretation; and revision of  
15 the article prior to publication.  
16  
17

18 *Ms. Prentice:* Contributed to the data acquisition, analysis and interpretation.  
19

20 *Dr. Sandin:* Contributed to the conception, hypothesis delineation, and design of the study; and  
21 revision of the article prior to publication.  
22  
23  
24  
25  
26  
27  
28

29 **Data Sharing:** There is no additional data available.  
30  
31  
32  
33

34 **Financial/nonfinancial disclosures:** The authors report that no potential conflicts of interest  
35 exist with any companies/organizations whose products or services may be discussed in this  
36 article.  
37  
38  
39  
40  
41  
42

#### 43 **Role of sponsors:**

44 The material is the result of work supported with resources and use of facilities at the  
45 Moffitt Cancer Center (Drs. Robinson, Smith and Sandin) and the University of Washington (Dr.  
46 SenGupta and Ms. Prentice).  
47  
48  
49  
50

51 Bacteria were identified by the Molecular Microbiology Laboratory at the University of  
52 Washington Medical Center. <http://depts.washington.edu/molmicdx/>.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The views expressed herein do not necessarily represent the views of the funding agency  
4  
5 (The Hoenle Foundation), the Moffitt Cancer Center or the University of Washington.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

1. American Thoracic Society. Statement on sarcoidosis. *Am J Respir Crit Care Med* 1999;160:736-55.
2. Rybicki BA, Maliarik MJ, Major M, Popovich JJ, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. *Semin Respir Infect* 1998;13:166-73.
3. Iannuzzi MC, Brybicki BA, Teirstein AS. Sarcoidosis. *New Engl J Med* 2007;357:2153-65.
4. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. *Am J Respir Crit Care Med* 2011;183:573-81.
5. Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a metanalysis. *Europ Respir J* 2007;30:508-16.
6. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, et al. A case control etiologic study of sarcoidosis. *Am J Respir Crit Care Med* 2004;170:1324-30.
7. DuBois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? *J Intern Med* 2003;2003:4-17.
8. de Sanctis JT, Carpenter CF, Sims MD, et al. Culture-negative endocarditis and the use of molecular diagnostics. *Infect Dis Clin Med* 2010;18:120-3.
9. Itoh S, Kazumi Y, Abe C, Takahashi M. Heterogeneity of RNA polymerase gene (*rpoB*) sequences of *Mycobacteria gordonae* clinical isolates identified with a DNA probe kit and by conventional methods. *J Clin Micro* 2003;41:1656-63.
10. Measuring Usability: A/B Test Calculator., 2012. (Accessed April 7, 2013, at <http://www.measuringusability.com/ab-calc.php#comments.>)
11. Social Security Death Index. 2013. (Accessed April 7, 2013, at <http://www.genealogybank.com/gbnk/ssdi/?kbid=9064&m=9.>)
12. Li N, Bajoghi A, Kubba A, Bhawan J. Identification of mycobacterial DNA in cutaneous lesions of sarcoidosis. *J Cutan Path* 1999;26:271-8.
13. Eishi Y, Suga M, Kobayashi D, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. *J Clin Micro* 2002;40:198-204.
14. Drake WP, Pei Z, Pride DT, Collins RD, Cover TL, Blaser MJ. Molecular analysis of sarcoidosis tissues for *Mycobacterium* species DNA. *Emerg Infect Dis* 2002;8:1334-41.
15. Ichikawa H, Kataoka M, Hiramatsu J, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. *Sarcoid Vasc Diffuse Lung Dis* 2008;25:15-20.
16. Ishige I, Takemura T, Kobayashi L, et al. *Propionibacterium acnes* is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. *Sarcoid Vasc Diffuse Lung Dis* 2005;22:33-42.
17. Rubin EJ. The granuloma in tuberculosis--Friend or foe? *N Engl J Med* 2009;360:2471-3.
18. Iannuzzi MC, J.R. F. Sarcoidosis, clinical presentation, immunopathogenesis and therapeutics. *J Amer Med Assoc* 2011;305:391-9.
19. McFadden JJ, Fidler HM. Mycobacteria as possible causes of sarcoidosis and Crohn's disease. *J Appl Bacter* 1996;81:47S-52S.
20. Motiwala AS, Li L, Kapur V, Sreevatsan S. Current understanding of the genetic diversity of *Mycobacterium avium* subspecies *paratuberculosis*. *Microb Infect* 2006;8:1406-18.

21. Chamberlain W, Borody TJ, Campbell J. Primary treatment of Crohn's disease: combined antibiotics taking center stage. *Expert Rev Clin Immunol* 2011;7:751-60.
22. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. *Amer J Gastro* 2011;106:661-73.
23. Das K, Seril DN. *Mycobacterium avium* subspecies *paratuberculosis* in Crohn's disease: The puzzle continues. *J Clin Immun* 2012;46:627-8.
24. Nicoletti F, Conrad D, Wang A, et al. 16alpha-bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. *Clin Experl Immun* 2009;158:308-16.
25. Stickney DR, Novelijic Z, Garsd A, Destiche DA, Frincke JM. Safety and efficacy of immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. *Antimicrob Agents Chemo* 2007;51:2639-41.
26. Edelson E. Isoniazid in the treatment of sarcoidosis; a preliminary report. *J Invest Derm* 1953;21:71-4.
27. Sahasranaman V, Tucci VT, Vincent AL, Sandin RL, Greene JN. The clinical manifestations, diagnosis and treatment of non-tuberculous mycobacteria infections. *J Gen Med* 2008;20:31-45.
28. Israel HL, Sones M, Harrell D. Ineffectiveness of isoniazid and iproniazid in therapy of sarcoidosis. *Am Rev of Tubercul* 1953;67:671-3.
29. Holsinger RE, Dalton JE. Isoniazid therapy in cutaneous tuberculosis and sarcoidosis. *J Amer Med Assoc* 1954;154:475-81.
30. Hoyle C, Dawson J, Mather G. Treatment of pulmonary sarcoidosis with streptomycin and cortisone. *Lancet* 1955;268:638-43.
31. Chatterjee SC, Ghosh JC. Sarcoidosis treated with anti-tuberculous drugs. *J Ind Med Assoc* 1957;29:61-3.
32. James DG, Thomson AD. The course of sarcoidosis and its modification with treatment. *Lancet* 1959;1:1057-61.
33. Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: A review for the pulmonologist. *Chest* 2009;136:583-96.

## ABBREVIATIONS

BMI = body mass index

CD4+ T cells = cluster of differentiation 4 thymic lymphocyte cells

CT = computed tomography

DNA = deoxyribonucleic acid

MAP = *Mycobacterium avium* subspecies *paratuberculosis*

PCR = polymerase chain reaction


PET = positron emission tomography

RNA = ribonucleic acid

rRNA PCR = ribosomal ribonucleic acid PCR

16S rDNA= 16 subunit of ribosomal DNA

TNF- $\alpha$  = tumor necrosis factor-alpha



**Fig. 1. Contrast-enhanced computed chest tomography at 2 different axial levels showing typical symmetrical hilar and mediastinal adenopathy**

Contrast-enhanced computed chest tomography at 2 different axial levels showing typical symmetrical hilar and mediastinal adenopathy

225x169mm (72 x 72 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Fig 2. PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph nodes**

PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph nodes (arrows)

225x169mm (72 x 72 DPI)

ew only

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract <a href="#">Page 1, 3, 4</a>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
<b>Introduction</b>			
Background/rationale <a href="#">Pages 5-6</a>	2	Explain the scientific background and rationale for the investigation being reported	
Objectives <a href="#">Pages 5-6</a>	3	State specific objectives, including any pre-specified hypotheses	
<b>Methods</b>			
Study design <a href="#">Page 6</a>	4	Present key elements of study design early in the paper	
Setting <a href="#">Pages 6-7</a>	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants <a href="#">Pages 7-8</a>	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables <a href="#">Pages 6-7</a>	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/ measurement <a href="#">Pages 6-7</a>	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size <a href="#">Not applicable in this case control observational trial</a>	10	Explain how the study size was arrived at	
Quantitative variables <a href="#">Pages 6-7</a>	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods <a href="#">Pages 6, 7, 9</a>	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants <a href="#">Table 1</a>	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data <a href="#">Table 1</a>	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data <a href="#">Tables 1 and 2</a>	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results <a href="#">Tables 1 and 2</a>	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses <a href="#">Not applicable</a>	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion <a href="#">Discussion section</a></b>			
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability <b>Conclusion section</b>	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding <a href="#">Title page</a>	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	



1  
2  
3  
4  
5 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

6 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
7 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
8 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



**MOLECULAR ANALYSIS OF SARCOIDOSIS LYMPH NODES  
FOR MICROORGANISMS: A CASE-CONTROL STUDY WITH  
CLINICAL CORRELATES**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004065.R1
Article Type:	Research
Date Submitted by the Author:	31-Oct-2013
Complete List of Authors:	Robinson, Lary; Moffitt Cancer Center, Thoracic Oncology Smith, Prudence; Moffitt Cancer Center, Pathology SenGupta, Dhruva; Uiversity of Washington, Laboratory Medicine Prentice, Jennifer; Uiversity of Washington, Laboratory Medicine Sandin, Ramon; Moffitt Cancer Center, Pathology
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Infectious diseases, Immunology (including allergy), Respiratory medicine
Keywords:	BACTERIOLOGY, Adult thoracic medicine < THORACIC MEDICINE, Inflammatory bowel disease < GASTROENTEROLOGY, Epidemiology < INFECTIOUS DISEASES, Thoracic medicine < INTERNAL MEDICINE, MICROBIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title: **“MOLECULAR ANALYSIS OF SARCOIDOSIS LYMPH  
NODES FOR MICROORGANISMS: A CASE-CONTROL STUDY  
WITH CLINICAL CORRELATES”**

Running Head: Sarcoidosis and Bacteria

Authors: Lary A. Robinson, M.D., FCCP† <lary.robinson@moffitt.org>

Prudence Smith, M.D. \* <prudence.smith@moffitt.org>

Dhruba J. SenGupta, Ph.D.‡ <dsengup@u.washington.edu>

Jennifer L. Prentice, MS, MT, (ASCP)‡ <jprentic@seattlecca.org >

Ramon L. Sandin, M.D.\* <ramon.sandin@moffitt.org>

Institutions: †Center for Infection Research in Cancer, Division of Thoracic Oncology, Moffitt  
Cancer Center, Tampa, FL, USA.

\*Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.

‡Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

Corresponding Author: Lary A. Robinson, M.D., Department of Thoracic Oncology, Moffitt

Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel: (813) 745-6895.

FAX (813) 745-3027. Email <lary.robinson@moffitt.org>

Conflict of Interest: None of the authors has any personal or financial support, nor author  
involvement with any organization with financial interest in the subject matter.

Research Support: This project was supported by a grant from the W. Paul Hoenle Foundation,  
Sarasota, Florida 34242, USA

Text Word Count: 2999 Abstract Word Count: 250

Keywords: Sarcoidosis; Atypical mycobacteria; Polymerase chain reaction; *Propionibacterium  
acnes*

## ABSTRACT

**INTRODUCTION:** Sarcoidosis is an incurable, chronic granulomatous disease primarily involving the lungs and lymph nodes of unknown etiology, treated with non-specific anti-inflammatory/immunosuppressive drugs. Persistently symptomatic patients worsen with a disabling, potentially fatal clinical course. To determine a possible infectious cause, we correlated in a case control study clinical information with the presence of bacterial DNA in sarcoidosis mediastinal lymph nodes compared to control lymph nodes resected during cancer surgery.

**METHODS:** We retrospectively studied formalin-fixed, paraffin-embedded, mediastinal lymph nodes from 30 sarcoidosis patients and 30 control lung cancer patients. Nucleic acids were extracted from nodes, were evaluated by rRNA PCR for bacterial 16S rDNA, and the result was sequenced and compared to a bacterial sequence library. Clinical information was correlated.

**RESULTS:** 11/30 (36.7%) of lymph nodes from sarcoidosis patients had detectable bacterial DNA, significantly more than control patient lymph nodes (2/30, 6.7%),  $p = 0.00516$ . At presentation, 19/30 (63.3%) sarcoidosis patients were symptomatic including all patients with detectable bacterial DNA. Radiographically, there were 18 Stage I and 12 Stage II patients. All Stage II patients were symptomatic and 75% had PCR-detectable bacteria. After a mean follow-up of  $52.8 \pm 32.8$  months, **all** patients with PCR-detectable bacteria in this series were persistently symptomatic requiring treatment.

**DISCUSSION:** 36.6% of sarcoidosis patients had detectable bacteria DNA on presentation, **all of these patients** were quite symptomatic, and most were radiographically-advanced stage II.. These findings suggest bacterial DNA-positive, symptomatic patients have more aggressive

1  
2  
3 sarcoidosis that persists long term, and might benefit from antimicrobial treatment directed  
4  
5  
6 against this presumed chronic granulomatous infection.  
7  
8  
9  
10

## 11 12 13 **ARTICLE SUMMARY:**

### 14 15 16 17 *ARTICLE FOCUS:*

- 18  
19  
20 • Sarcoidosis is a common yet incurable, chronic granulomatous disease of  
21  
22 unknown etiology treated with non-specific anti-inflammatory and/or  
23  
24 immunosuppressive drugs.  
25  
26
- 27  
28 • Persistently symptomatic patients worsen despite treatment with a disabling,  
29  
30 potentially fatal clinical course.  
31
- 32  
33 • We propose that sarcoidosis results from a chronic granulomatous infection from  
34  
35 a treatable pathogen in certain susceptible individuals, much like granulomatous  
36  
37 ileitis (Crohn's disease) which shows an encouraging response to multi-drug  
38  
39 antimicrobial therapy.  
40  
41  
42

### 43 44 *KEY MESSAGES:*

- 45  
46 • This case-control, retrospective study correlated clinical outcomes with the  
47  
48 presence of detectable bacterial DNA in sarcoidosis lymph nodes versus control  
49  
50 lymph nodes.  
51  
52
- 53  
54 • The entire group of sarcoidosis patients had significantly more detectable  
55  
56 bacterial DNA than control patient lymph nodes.  
57  
58  
59  
60

- However, **all** persistently symptomatic patients have detectable bacterial DNA in their lymph nodes suggesting they have more aggressive sarcoidosis that potentially might benefit from antimicrobial treatment directed against a presumed chronic granulomatous infection.

#### *STRENGTHS AND LIMITATIONS:*

- Although a number of prior studies have demonstrated the consistent presence of bacterial DNA (mostly atypical mycobacteria and *Propionibacterium acnes*) in sarcoidosis tissue, the current study is the first to correlate clinical outcomes with the presence of detectable bacterial DNA, suggesting the most promising candidates for treatment.
- Nevertheless, the molecular approach to bacterial detection has distinct limitations including possible false-positive results secondary to contaminated PCR reagents, the paraffin imbedding process, or post-embedding handling and processing of the paraffin block. Also the mere physical presence of the bacterial DNA in the lymph nodes does not prove that the disease is caused by the microorganism.
- Additionally, the number of lymph nodes positive for bacterial DNA may be significantly underestimated because of the tendency of the formalin-fixation and paraffin embedding process to breakdown prokaryotic DNA.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## INTRODUCTION

Sarcoidosis is a multisystem, granulomatous disease whose etiology is obscure and controversial. Nevertheless, the condition is relatively common with a significantly higher age-adjusted annual incidence in African-Americans (35.5 cases per 100,000) versus Caucasian-Americans (10.9 cases per 100,000). An estimated one million people in the U. S. have this disease. Based on the current U.S. population of 315,556,000, there will be approximately 38,605 new cases of sarcoidosis this year and just over 1000 (2.6%) will die of the illness.<sup>1,2</sup>

The fundamental pathologic abnormality in the disease is the formation of non-caseating epithelioid granulomas, which usually confine poorly soluble foreign material that simply cannot be removed by a single phagocytic cell. The key feature in sarcoidosis is activated CD4+ T cells which differentiate into type 1 helper T cells (Th1), secreting interleukin-2 and interferon- $\gamma$ , augmenting macrophage TNF- $\alpha$ , and amplifying the local cellular immune response.<sup>3,4</sup> This granulomatous inflammation interferes with local tissue homeostasis leading to organ impairment.

Since sarcoidosis primarily involves the lungs, eyes and skin, attention has focused on airborne environmental antigens that might trigger this presumed hypersensitivity response with its T cell-mediated cellular immune response.<sup>3</sup> Similar granulomatous responses can be seen from a variety of infectious agents including mycobacteria, parasites (schistosoma), and fungi (coccidiomycosis). Early studies reported associations with non-infective agents including beryllium, zirconium, aluminum, wood-burning stoves, tree pollen, clay soil, talc, insecticides, inorganic particles, and moldy environments, but none of these theoretical causes has endured.<sup>3,5,6</sup> There is also a several-fold increased incidence of sarcoidosis occurring in siblings



1  
2  
3 and parents, as well as a consistent strong association with specific gene products such as class I  
4 and class II HLA antigens, which may add to the familial connection.  
5  
6

7  
8 Although no infectious agent has been cultured directly from sarcoidosis tissues, clinical  
9 and immunologic characteristics of the disorder provide the strongest support for a microbial  
10 etiology, at least in some patients.<sup>5-7</sup> To explore a possible infectious cause in patients seen at the  
11 Moffitt Cancer Center, we correlated the clinical presentation and long-term follow-up of  
12 sarcoidosis patients with the presence of bacterial DNA in archived, surgically-resected  
13 mediastinal lymph nodes. Results from sarcoidosis nodes were compared to control lymph nodes  
14 resected at the time of lung surgery in node-negative, Stage I non-small cell lung cancer patients.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **METHODS**

### 28 *Regulatory Oversight*

29  
30 Tissue and clinical data in this case-control study was obtained after approval by the  
31  
32 Moffitt Cancer Center Scientific Review Committee Protocol MCC #16131 and the University  
33 of South Florida IRB Protocol #108656.  
34  
35  
36  
37  
38  
39  
40

### 41 *Study Design*

42  
43 By searching the Moffitt Cancer Center surgical pathology database between January 1,  
44 2000 and April 1, 2010, we retrospectively identified 30 randomly-chosen patients who were  
45 diagnosed with sarcoidosis based on the typical radiographic and clinical presentation, and the  
46 histologic finding of non-caseating epithelioid granulomata in lymph nodes obtained sterilely  
47 only by mediastinoscopy, to avoid possible microorganism contamination by endoscopic  
48 biopsies. Special stains for microorganisms were negative on the specimens. For inclusion in  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 this group, the following criteria were used to make the diagnosis of sarcoidosis: 1) chest  
4 radiograph and chest CT findings of symmetrical mediastinal and hilar adenopathy with or  
5 without reticulonodular infiltrates in the lung fields (see Figure 1); 2) when performed, PET  
6 scans demonstrated glucose avidity in the enlarged lymph nodes (see Figure 2); 3) asymptomatic  
7 presentation or typical symptoms of dyspnea, cough, chest tightness/pain, night sweats, fevers,  
8 fatigue, malaise, skin rash or weight loss; 4) lymph nodes showing histologic features of  
9 confluent, non-caseating granulomata; and 5) any known microorganism causes of granulomata  
10 were excluded by history or culture. All histopathologic specimens were reviewed by one of us  
11 (P.S.) to reconfirm the diagnosis made originally by departmental pathologists at Moffitt.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 To insure sterile collection, all control specimens were taken from lymph nodes removed  
26 at open thoracotomy by one of us (L.R.) in 30 (1:1 match with cases) randomly-chosen patients  
27 with Stage IA non-small lung cancer. Lymph nodes were selected only from patients with small  
28 peripheral tumors, no obstructive atelectasis, and no evidence of active infection. One of us (P.S)  
29 reviewed all control lymph node histology to verify there were no metastases, acute  
30 inflammation, or granulomata.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 *Clinical Data*

42  
43 Clinical data on the patient demographics, initial presenting symptoms and objective  
44 findings were extracted from the electronic medical record on all sarcoidosis patients by one of  
45 us (L.R.). Patients were staged using the modified Scadding radiographic staging system: stage 0  
46 normal chest x-ray; stage 1 hilar and mediastinal adenopathy alone; stage 2 adenopathy and  
47 pulmonary infiltrates; stage 3 pulmonary infiltrates alone; and stage 4 pulmonary fibrosis.<sup>4</sup> Long-  
48 term follow-up clinical status and subsequent treatment regimens for all sarcoidosis patients were  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 obtained from the electronic medical record and telephone calls placed to the patients or their  
4  
5 immediate family.  
6  
7  
8  
9

### 10 *DNA Extraction*

11  
12 De-identified, formalin-fixed, paraffin-embedded blocks of lymph nodes from sarcoidosis  
13 and control patients were sent to the Departments of Laboratory Medicine and Microbiology at  
14 the University of Washington (Seattle, WA), where investigators were blinded as to the identity  
15 of the specimens. The DNA extraction from paraffin-embedded blocks was performed after  
16 paraffin was removed by incubation in xylene using the Roche HighPure PCR template  
17 purification kit (Roche Diagnostics GmbH, Mannheim, Germany).<sup>8</sup> Several negative patient  
18 samples (unrelated to the present study) were included in each batch to rule out contamination.  
19 Inhibition was ruled out by checking the ability of exogenously added target DNA to be  
20 amplified in the same PCR mix that contained DNA extracted from clinical specimen.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 *Mycobacterium tuberculosis* and *Bartonella henselae* have been detected multiple times in the  
35 past using these PCR assays. 16S primers used were broad range for all bacteria. hsp65 and  
36 rpoB were broad range for Mycobacteria spp only. 16S PCR detected non-Mycobacterium  
37 species DNA such as *Propionibacterium acnes*. Mycobacterium sp. DNA were detected by  
38 hsp65 and/or rpoB primers. Primers used for amplification were also used for amplicon  
39 sequencing. The PCR amplicon was directly sequenced; no cloning was performed. Mixed  
40 infection was not detected in this set of specimens. For alignment, BLASTN was used.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 Identification was based on exact match on all cases. No sequence that could not be linked to a  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 *P. acnes* was detected by 16S primers and *M. avium* was detected by hsp65 primers.

4  
5  
6 *Mycobacterium avium* was detected and identified by sequence analysis.

7  
8  
9  
10  
11 *PCR Analysis for 16S ribosomal DNA, Heat Shock Protein 65(hsp65), RNA polymerase subunit*  
12  
13 *(rpoB)*

14  
15 The 16S gene fragment was amplified as previously described.<sup>8</sup> The hsp65 gene was  
16 amplified using TB11 and TB12 primers, and the RNA polymerase subunit gene (rpoB) was  
17 amplified using MF and MR primers.<sup>9</sup> The amplified products were then sequenced using the  
18 Big Dye Sequencing kit (Applied Biosystems, Foster City, CA) using the vendor's recommended  
19 protocol. The sequences of two strands were assembled into doubled-stranded contig using  
20 Sequencher software (Gene Codes, Ann Arbor, MI). The final sequences were used to search the  
21 National Center for Biotechnology Information (National Institutes of Health) database using  
22 BLAST (Basic Local Alignment Search Tool) to identify the amplified DNA.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 *Quantitative Variables*

38  
39 The primary variable to be compared between the sarcoidosis and controls patients is the  
40 number of patients in each group with bacterial DNA found in lymph nodes. The N-1 Two  
41 Proportion test for comparing independent proportions for small sample sizes is used to compare  
42 the results between the two groups.<sup>10</sup> Additionally, odds ratios with 95% confidence intervals  
43 were calculated.<sup>11</sup> All numerical data is expressed as the mean  $\pm$  standard deviation.  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 **RESULTS**  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Demographic and clinical characteristics of the 30 sarcoidosis study patients are found in  
4  
5 Table 1.  
6

7  
8 *Demographics*  
9

10 Patient ages are: mean  $52.5 \pm 12.3$  years (median 53 years, range 30-75 years). The  
11  
12 male:female ratio is 14:16. The ethnicity: Caucasian 73.3% (22), African-American 16.7% (5),  
13  
14 and Hispanic 10% (3). Most patients were overweight: mean BMI  $31.4 \pm 6.9$ , median 28.5, range  
15  
16 18.8-47.3.  
17

18  
19  
20 *Clinical Presentation*  
21

22 At the time of initial presentation, 19 of 30 patients (63.3%) were symptomatic, usually  
23  
24 with multiple symptoms. Of these 19 patients, the duration of symptoms before diagnosis was a  
25  
26 mean  $22.1 \pm 30.0$  months (median 12 months, range 1-120 months). The most common  
27  
28 symptoms were night sweats 9 (30.0%); dyspnea 8 (26.7%); chest pain 7 (23.3%); chest  
29  
30 tightness 5 (16.7); fevers 3 (10.0%); fatigue 3 (10%); skin rash 2 (6.7%); and stomach ulcer 2  
31  
32 (6.7%). Other symptoms present in at least one patient include: dyspepsia, dysphagia, diarrhea,  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Sarcoidosis Patient Results

No.	Age/ Sex	Race	X-ray Stage	Pack-Year Smoking	Prior Cancer	Chemo	PCR Result on Lymph Nodes	Initial Symptoms (year)	Follow- up (mo.)	Current Status (Long-Term)
1	41/F	AA	I	7	Uterine	No	<i>Mycobacteria chelonae</i>	Yes (2009)	36	Sympt., alive
2	63/F	C	II	20	Breast	Yes	<i>Mycobacteria chelonae</i>	Yes (2008)	12	Sympt., deceased from COPD 2009
3	64/F	C	II	None	None	No	<i>Mycobacteria mucogenicum</i>	Yes (2008)	41	Sympt., alive
4	43/M	C	I	None	Melanoma	No	Negative	No (2009)	31	Asympt., alive
5	61/F	C	I	None	Synovial cell sarcoma	Yes	Negative	No (2009)	23	Asympt.; new endomet. ca, alive
6	39/M	C	II	5	None	No	<i>Propionibacterium acnes</i>	Yes (2008)	35	Sympt., alive
7	58/M	C	I	3	Tonsil cancer	Yes	<i>Corynebacterium propinquum</i>	Yes (2006)	65	Sympt.; tonsil ca. relapse, alive
8	54/M	C	II	None	None	No	<i>Propionibacterium acnes</i>	Yes (2006)	60	Sympt., alive
9	52/F	AA	I	6	None	No	Negative	Yes (2007)	58	Sympt., alive
10	53/F	C	I	5	Melanoma	Yes	Negative	No (2007)	53	Asympt., alive
11	34/M	AA	II	None	None	No	<i>Propionibacterium acnes</i>	Yes (2007)	53	Sympt., alive
12	40/M	C	I	Cigars	None	No	Negative	Yes (2007)	36	Sympt., alive
13	49/M	AA	II	None	None	No	<i>Duganella zoogloeoides</i>	Yes (2010)	Lost	Unknown, alive
14	57/F	AA	II	5	Breast	Yes	<i>Propionibacterium acnes</i>	Yes (2000)	136	Sympt; breast ca. relapse; polymyalgia rheumatica; Hashimoto's thyroiditis, alive
15	67/M	C	I	None	None	No	Negative	No (2001)	Lost	Unknown, alive
16	30/M	H	I	None	None	No	Negative	No (2001)	Lost	Unknown, alive
17	75/F	C	I	None	Ovarian	Yes	Negative	No (2002)	36	Asymptomatic, deceased from ca., 2005
18	67/F	C	I	50	Liposarcom a	No	Negative	No (2003)	106	Sympt., alive
19	60/F	C	I	None	Nerve sheath tumor	No	Negative	No (2003)	60	Asympt., deceased unknown cause 2008
20	41/F	C	I	None	None	No	Negative	No (2005)	78	Asympt., alive
21	50/F	C	I	None	None	No	Negative	Yes (2005)	73	Asympt., alive
22	48/F	C	I	None	Breast	Yes	<i>Propionibacterium acnes</i>	Yes (2003)	24	Sympt.; deceased from ca. 2005
23	41/F	C	II	None	Adrenal ca; melanoma	Yes	Negative	Yes (2006)	4	Deceased from ca. 2007
24	35/M	H	I	2.5	None	No	Negative	Yes (2006)	24	Asympt., alive
25	32/M	C	I	1.0	None	No	Negative	No (2006)	Lost	Unknown, alive
26	37/M	C	II	15	Hodgkin's disease	Yes	<i>Propionibacterium acnes</i>	Yes (2007)	66	Sympt., alive
27	51/F	AA	II	None	None	No	Negative	No (2007)	64	Sympt; (mildly), alive
28	56/F	C	II	None	Colon ca.	Yes	Negative	No (2008)	Lost	Unknown, alive
29	33/M	C	I	5	Melanoma	No	Negative	No (2009)	38	Asympt., alive
30	52/F	H	II	1	Uterine	No	Negative	Yes (2002)	48	Asympt., alive

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 abbreviations: AA = African-American; Asympt. = asymptomatic; C = Caucasian; Ca. = cancer; Chemo = chemotherapy; COPD = chronic obstructive pulmonary disease; H = Hispanic; Sympt. = symptomatic. All patients positive on PCR for microorganism DNA in lymph nodes are shown in bold type.

For peer review only

1  
2  
3 constipation, kidney stones, joint and muscle pains, orthopnea, nose and mouth skin lesions,  
4  
5 intermittent bronchospasm, malaise, and weight loss.  
6  
7

8 Co-morbidities: asthma 2 (6.7%); coronary artery disease 2 (6.7%); diabetes mellitus 4  
9  
10 (13.3%); hypertension 5 (16.6), and one each of gout, hypothyroidism, eczema, fibromyalgia,  
11  
12 and Crohn's disease. Malignancies were extremely common with over half (53.3%) having a  
13  
14 current or prior tumor, a finding noted previously by others.<sup>12</sup> The malignancies prior to or at the  
15  
16 time of presentation are: breast 3, melanoma 3, uterine 2, sarcomas 3, tonsil 1, ovary 1, adrenal 1,  
17  
18 colon 1, and Hodgkin's lymphoma 1.  
19  
20  
21

### 22 23 24 *Radiographic Studies*

25  
26  
27 Chest CT was performed on all 30 patients and all had symmetrical mediastinal and hilar  
28  
29 adenopathy. Four of 30 (13.3%) had obvious abdominal adenopathy. Lung nodules were present  
30  
31 in 12 patients (40.0%) and were radiographic Stage II sarcoidosis. The other 18 patients (60.0%)  
32  
33 had Stage I disease. All 12 Stage II patients were symptomatic. PET/CT scans were done in 25  
34  
35 of 30 sarcoidosis patients. All demonstrated glucose avidity in the enlarged mediastinal and hilar  
36  
37 nodes (see Figure 2 for typical example), and glucose avidity was seen in the abnormal  
38  
39 abdominal nodes in the 4 patients with radiographic adenopathy below the diaphragm.  
40  
41  
42  
43  
44  
45

### 46 47 *Laboratory Results*

48  
49 Twelve of 30 patients had lymph node tissue sent at the time of mediastinoscopy for  
50  
51 aerobic, fungal and mycobacterial cultures. All cultures showed no growth after six weeks  
52  
53 incubation.  
54  
55  
56  
57  
58  
59  
60



### *Bacterial DNA Detected by PCR*

Eleven of 30 lymph nodes (36.7%) in sarcoidosis patients had bacterial DNA present by PCR. Only 2 of 30 (6.7%) control patients were found to have bacterial DNA in their lymph nodes. The microorganisms present in each group are shown in Table 2. There are significantly more sarcoidosis patient lymph nodes positive for microorganism DNA than control lymph nodes: 11/30 versus 2/30,  $p = 0.00516$  (2-tailed  $p$ -value); the odds ratio is 8.1053 with 95% confidence intervals 1.6115-40.7675,  $p = 0.0111$ .

All sarcoidosis patients with detectable bacterial DNA in lymph nodes (36.7%) were symptomatic at presentation. Additionally, 73% (8/11) of bacterial DNA-positive sarcoidosis patients were both symptomatic at presentation and had radiographic Stage II disease.

### *Long-Term Follow-up*

Long-term follow-up was complete in 25 of 30 (83.3%) of sarcoidosis patients, for a mean follow-up of  $50.4 \pm 28.2$  months (median 48 months, range 4 -132 months). Five of these patients are deceased: 3 from cancers, 1 from chronic obstructive pulmonary disease, and one from unknown causes. The other five patients lost to direct follow-up are still living based on information obtained from the Social Security Death Index.<sup>13</sup>

Of the 10 sarcoidosis patients with bacterial DNA found in their lymph nodes in this series in whom long-term follow-up was available, **all** were symptomatic at follow-up a mean  $52.8 \pm 32.4$  months (median 47 months, range 12-136 months). The one additional bacterial DNA-positive patient was lost to follow-up.

**Table 2. Bacterial DNA detected by PCR****Sarcoidosis (11/30)***Propionibacterium acnes*: 7*Mycobacterium**chelonae*: 2*mucogenicum*: 1*Duganella zoolooides*: 1*Corynebacterium propinquum*: 1**Control (2/30)***Mycobacterium avium*: 1*Propionibacterium acnes*: 1

## DISCUSSION

The objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial DNA by molecular methods and b) correlate the results with clinical characteristics of the patients.

### *Bacterial DNA*

As expected, our molecular testing using PCR demonstrated that over one-third of sarcoidosis patients (36.7%) had evidence of bacterial DNA in the nodes, indicating either past or current involvement with these microorganisms. This percentage of bacterial DNA-positive specimens falls in the range found in numerous prior published studies from the last two decades (using various methodologies), which range from 26%-80% positive (Table 3<sup>5,7,14-17</sup>).

Furthermore, atypical mycobacteria and *Propionibacterium acnes* represented almost all DNA identified, also consistent with the findings of the multiple prior studies (Table 3). Additionally identified were one skin and mucous membrane organism (*Corynebacterium propinquum*), and one aerobic Gram negative bacillus (*Duganella zoogloeoides*) that is usually found in aqueous environments. Interestingly, the latter patient (no. 13) with *Duganella zoogloeoides* was an asbestos technician originally from tropical Haiti. As a disclaimer, just the finding of DNA from a microorganism in lymph nodes does not tell us whether the viable organism is present or whether it caused the granulomatous reaction.

Similar to prior published studies summarized in Table 3, significantly less (only 2 of 30 or 6.7%,  $p = 0.00516$ ) of control lymph nodes resected at the time of lung cancer surgery showed

evidence of bacterial DNA (*Mycobacterium avium* and *Propionibacterium acnes*). This difference strongly suggests that the demonstration of bacterial DNA in sarcoidosis lymph

**Table 3. Selected studies of DNA of infectious agents found in sarcoidosis tissues**

Author/Year	Sarcoid Tissue (No. patients)	Technique	Organisms (%)	Control No. (% organisms)
Li, 1999 <sup>11</sup>	Skin (20)	PCR (restriction enzyme pattern)	<i>Mycobacteria</i> (2 <i>tuberculosis</i> , 14 other <i>mycobacteria</i> . 80% total positive)	20 Normals (0% organisms)
Du Bois, 2003 <sup>7</sup> (Review of pre-1999 studies)	Lymph nodes (12 studies with 295 patients)	PCR (various methods)	<i>Mycobacterium</i> sp. (34%)	Various
Eishi, 2002 <sup>12</sup> (5 center study)	Lymph nodes (108)	Quantitative real-time PCR	<i>P. acnes</i> (72%) <i>P. granulorum</i> (55%) <i>M. tuberculosis</i> (4%) <i>E. coli</i> (2%)	86 Normals (29% <i>P. acnes</i> , 12% <i>P. granulorum</i> , 2% <i>M. tuberculosis</i> )
Drake, 2002 <sup>13</sup>	Lymph nodes (25)	Nested PCR	<i>Mycobacterium</i> sp. (60%)	25 Normals (0%)
Gupta, 2007 <sup>5</sup> (metanalysis)	Various (31 studies with 874 patients)	PCR (various methods)	<i>Mycobacterium</i> sp. (26%)	745 Controls (3%)
Ichikama, 2008 <sup>14</sup>	Bronchoalveolar lavage (42)	Quantitative PCR	<i>Propionibacterium</i> sp. (3X higher genome levels vs. controls)	30 Controls (low levels same genome)

1  
2  
3 nodes is a real finding in our study (and in over 35 prior published studies) and they are not just  
4  
5 processing contaminants, therefore pointing to microorganisms as potential contributors to the  
6  
7 genesis of this disease. In addition, *Propionibacterium acnes* DNA was found in only 1 of 30  
8  
9 (3.3%) control lymph nodes in our study, in stark contrast to Ishige and associates in Japan who  
10  
11 reported this microorganism is an ubiquitous pulmonary lymph node commensal found in 8 of 11  
12  
13 (72.7%) non-sarcoid patients in their study.<sup>18</sup> Such a very high positive result in their study is  
14  
15 likely due to either geographical/ethnic/racial differences or potential contamination in processing.  
16  
17  
18  
19  
20  
21

### 22 *Clinical Characteristics*

23  
24 Perhaps the most intriguing findings came from correlation of the PCR findings with the  
25  
26 clinical information. All patients with lymph nodes containing bacteria DNA on presentation  
27  
28 were also highly symptomatic and 75% of them had the poorer-prognosis radiographic stage II  
29  
30 findings. Moreover, after a median 4 years follow-up, **all** bacterial DNA-positive patients were  
31  
32 *still* highly symptomatic. This striking correlation strongly suggests that demonstration of  
33  
34 bacterial DNA by PCR in lymph nodes on initial presentation is an adverse prognostic factor and  
35  
36 makes it unlikely that these patients will have a spontaneous remission.  
37  
38  
39  
40

41 Indeed, if infection with one of these microorganisms triggers an exuberant  
42  
43 granulomatous immune response, the 50-80% of patients who usually have a spontaneous  
44  
45 remission<sup>1</sup> likely clear the offending organism and the immune reaction subsides. We postulate  
46  
47 that those patients who have persisting symptomatic disease, likely continue to harbor the  
48  
49 microorganism which perpetuates the vigorous, destructive immune response, and as well as  
50  
51 permit the microorganism to travel elsewhere to other organs to create distant granulomatous  
52  
53 inflammation.  
54  
55  
56  
57  
58  
59  
60

### Limitations of Study

Many pathogenic microorganisms such as *Mycobacterium leprae* (leprosy) or coronaviruses (severe acute respiratory syndrome) cannot be grown directly in culture or they are very slow growing or difficult to culture such as *Tropheryma whippelii* (Whipple's disease).<sup>5,19</sup> In these instances, detection and identification rely on molecular mechanisms such PCR used in this study. Nevertheless, the molecular approach has distinct limitations including possible false-positive results secondary to contaminated PCR reagents, the paraffin imbedding process, or post-embedding handling and processing of the paraffin block. However in our study, thirty control lymph nodes were processed in an identical manner and bacterial DNA was detected in only 2/30 (6.6%), significantly less than the sarcoidosis nodes (36.7%,  $p = 0.00516$ ), suggesting that contamination is unlikely to account for the findings.

Another obvious limitation in interpreting the results of this and other prior molecular studies relates to colonization versus causation. Just the finding of microbial DNA in the nodes does not prove that the organism is actively involved in the pathogenesis of the disease. The microorganism may just be a commensal or theoretically it might even be attracted to the area of granulomatous inflammation. Nevertheless, the marked difference in the percentage of microbial DNA-positive nodes in sarcoidosis versus control patients is certainly suggestive of disease causation by the microorganisms.

Additionally, the number of lymph nodes positive for bacterial DNA may be significantly underestimated because of the tendency of the formalin-fixation and paraffin embedding process to breakdown prokaryotic DNA. Over time other investigators have found degradation of the prokaryotic bacteria DNA (especially mycobacteria) with aging of the paraffin-embedded

specimens.<sup>16</sup> Of note, the only 3 sarcoidosis lymph nodes positive for mycobacteria in our study were less than 3 years old when evaluated by PCR. Had we used fresh lymph node tissue like Drake and associates<sup>16</sup> who found 60% PCR positive for mycobacteria species, there may have been a much higher rate of positive bacterial DNA results (particularly mycobacteria) in our study.

### *Implications of the Study*

Sarcoidosis is a granulomatous disease primarily involving the lungs, lymph nodes and other organs that appears to be the result of an exuberant T cell and macrophage immunologic response to the continued presentation of a poorly degradable antigen. Numerous non-infective agents have been implicated based on epidemiologic basis but none have stood up to scrutiny.<sup>1,3,5</sup> The focus over the last two decades has been on infective agents that might trigger sarcoidosis, with the strongest suspects found in the mycobacteria family and the common commensal *Propionibacterium acnes*. And like classical tuberculosis where up to 90% of people infected with *Mycobacterium tuberculosis* remain in remission without treatment,<sup>20</sup> sarcoidosis also has a 65-80% spontaneous remission rate without treatment.<sup>1</sup> One may speculate that similar to tuberculosis, the immune system, after its initial response to a triggering microorganism, is successful in eradicating the agent and the immune response subsides. Then in the 20% or so with persistent and progressive sarcoidosis, the organism remains viable and perpetuates the destructive immune response.

Symptomatic sarcoidosis is usually treated with various anti-inflammatory and immunosuppressive agents such as corticosteroids, methotrexate and TNF-inhibitors

1  
2  
3 (biologics).<sup>21</sup> The similarities in immunologic abnormalities and treatment to another debilitating  
4  
5  
6 granulomatous disease, Crohn's disease, are striking.<sup>22</sup> Granulomatous ileitis (Crohn's) has been  
7  
8  
9 suspected by many investigators to be the result of a chronic infection with the obligate  
10  
11  
12 intracellular microorganism *Mycobacterium avium* subspecies *paratuberculosis* (MAP), that is  
13  
14 known to cause a granulomatous ileitis in cattle and other ruminants called Johne's disease.<sup>23</sup>  
15  
16 Although the classical treatment of Crohn's disease has been with immunosuppressive agents  
17  
18 just like with sarcoidosis, many recent studies suggest a much more effective treatment with less  
19  
20 side effects may be a triple antibiotic regimen geared toward the putative triggering agent  
21  
22 MAP.<sup>24-26</sup> In fact, many in the field suspect that this intracellular organism (MAP) that resides in  
23  
24 the macrophage impairs the normal autophagy that would usually eradicate the organism.<sup>24</sup>  
25  
26  
27 Agents that enhance autophagy such as 16 $\alpha$ -bromoepiandrosterone,<sup>27,28</sup> currently in human trials,  
28  
29  
30 may prove effective along with antibiotics in Crohn's disease.<sup>24</sup>  
31  
32

33  
34 Can some antibacterial/anti-mycobacterial regimen such as that used in Crohn's disease  
35  
36 alter the natural history of sarcoidosis in chronically symptomatic patients? Sixty years ago a  
37  
38 number of small trials using classical anti-tuberculous drugs (isoniazide, streptomycin, or  
39  
40 cortisone) were published with discouraging results.<sup>29</sup> However, atypical mycobacteria (rather  
41  
42 than *M. tuberculosis*) that are more likely to be one of the etiologic agents in sarcoidosis, are  
43  
44 almost all resistant to the standard anti-tuberculosis agents such as isoniazid.<sup>30-35</sup> And if other  
45  
46 organisms such as *Propionibacterium acnes* or perhaps cell-wall deficient (L-forms) bacteria  
47  
48 trigger and perpetuate sarcoidosis in some individuals, then the standard anti-tuberculous drugs  
49  
50 would also be ineffective.  
51  
52

53  
54 The tetracycline derivatives (minocycline and doxycycline), as well as the anti-malarial  
55  
56 drug chloroquine have been shown to be quite effective in treating cutaneous sarcoidosis.<sup>36</sup>  
57  
58  
59  
60



1  
2  
3 Minocycline can produce complete responses in up two-thirds of cases, although it is debated  
4  
5 whether this is an anti-microbial effect or an immunomodulating effect.<sup>37</sup>  
6  
7

8 Attention has recently turned to randomized sarcoidosis treatment trials with various anti-  
9  
10 microbial agents. W. P. Drake and associates just published positive results of the first  
11  
12 randomized trial (NCT01074554) of an anti-microbial regimen (directed at atypical  
13  
14 mycobacteria) in the United States using oral levofloxacin, ethambutol, azithromycin and  
15  
16 rifampin (CLEAR) to treat 30 patients with cutaneous sarcoidosis, with quite significant  
17  
18 reductions in cutaneous lesion size.<sup>38</sup> In 2012, D. Gupta and associates in their comprehensive  
19  
20 review of sarcoidosis and its similarities to tuberculosis presents a convincing case for anti-  
21  
22 tuberculous treatment of sarcoidosis.<sup>39</sup> D. Gupta is also the principal investigator in an ongoing  
23  
24 clinical trial in India using more standard anti-tuberculous therapy “Rifampicin and Isoniazid  
25  
26 Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot  
27  
28 Randomized Controlled Trial” (ClinicalTrials.gov Identifier: NCT01245036).<sup>40</sup> The results of  
29  
30 this trial in India with its high burden of tuberculosis will be available next year, though the drug  
31  
32 regimen used may not be as effective in countries with a low tuberculosis burden. If indeed  
33  
34 sarcoidosis arises from an abnormal immunologic response to a microorganism(s), the patient’s  
35  
36 geographical location may dictate which microorganism is involved and what anti-microbial  
37  
38 regimen will be most effective.  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 *Conclusions*

49  
50 Over the last three decades or more, numerous studies have examined every aspect of  
51  
52 sarcoidosis including its dysfunctional immune response. The primary therapy is immune  
53  
54 suppression in various forms but this treats only symptoms and does not seem to alter the natural  
55  
56  
57  
58  
59  
60

1  
2  
3 history of the disease.<sup>4,21</sup> Dozens of studies (Table 3) have repeatedly demonstrated evidence of  
4  
5 microorganisms in 30-80% of sarcoidosis tissues, mostly various mycobacteria and  
6  
7  
8 *Propionibacterium acnes*, and more of these molecular studies is not likely warranted.  
9

10 Perhaps we should follow the lead of the Crohn's disease gastroenterologists<sup>24,25</sup> and  
11  
12 proceed with a therapeutic clinical trial using a regimen of multiple antibiotics in persistently-  
13  
14 symptomatic, advanced stage sarcoidosis patients. Indeed, if there is a persistent, viable  
15  
16 microorganism infection causing the continuing or progressive debilitating symptoms and organ  
17  
18 failure, antibiotics might favorably impact the course of this disease.  
19  
20  
21  
22  
23  
24

## 25 **FIGURE LEGENDS**

26  
27 **Figure 1.** Contrast-enhanced computed chest tomography at 2 different axial levels showing  
28  
29 typical symmetrical hilar and mediastinal adenopathy.  
30

31  
32 **Figure 2.** PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph  
33  
34 nodes (arrows).  
35  
36  
37  
38  
39  
40  
41

## 42 **ACKNOWLEDGEMENTS**

43  
44  
45  
46 **Author contributorship:** Dr. Robinson had full access to all of the data in the study and takes  
47  
48 full responsibility for the integrity of the data and the accuracy of the data analysis.  
49

50  
51 *Dr. Robinson:* Contributed to the conception, hypotheses delineation and design of the study;  
52  
53 data acquisition, analysis and interpretation; and writing and revision of the article prior to  
54  
55 submission.  
56  
57  
58  
59  
60

1  
2  
3 *Dr. Smith:* Contributed to the conception, hypothesis delineation, and design of the study; data  
4 acquisition, analysis and interpretation; and revision of the article prior to publication.  
5  
6

7  
8 *Dr. SenGupta:* Contributed to the data acquisition, analysis and interpretation; and revision of  
9 the article prior to publication.  
10  
11

12 *Ms. Prentice:* Contributed to the data acquisition, analysis and interpretation.  
13

14  
15 *Dr. Sandin:* Contributed to the conception, hypothesis delineation, and design of the study; and  
16 revision of the article prior to publication.  
17  
18

19  
20  
21  
22 **Data Sharing:** There is no additional data available.  
23  
24

25  
26  
27 **Financial/nonfinancial disclosures:** The authors report that no potential conflicts of interest  
28 exist with any companies/organizations whose products or services may be discussed in this  
29 article.  
30  
31  
32

### 33 34 35 36 **Role of sponsors:**

37  
38 The material is the result of work supported with resources and use of facilities at the  
39 Moffitt Cancer Center (Drs. Robinson, Smith and Sandin) and the University of Washington (Dr.  
40 SenGupta and Ms. Prentice).  
41  
42  
43

44  
45 Bacteria were identified by the Molecular Microbiology Laboratory at the University of  
46 Washington Medical Center. <http://depts.washington.edu/molmicdx/>.  
47  
48

49  
50 The views expressed herein do not necessarily represent the views of the funding agency  
51 (The Hoenle Foundation), the Moffitt Cancer Center or the University of Washington.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. American Thoracic Society. Statement on sarcoidosis. *Am J Respir Crit Care Med* 1999;160:736-55.
2. Rybicki BA, Maliarik MJ, Major M, Popovich JJ, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. *Semin Respir Infect* 1998;13:166-73.
3. Iannuzzi MC, Brybicki BA, Teirstein AS. Sarcoidosis. *New Engl J Medicine* 2007;357:2153-65.
4. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. *Am J Respir Crit Care Med* 2011;183:573-81.
5. Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a metanalysis. *European Respiratory Journal* 2007;30:508-16.
6. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, et al. A case control etiologic study of sarcoidosis. *Am J Respir Crit Care Medicine* 2004;170:1324-30.
7. DuBois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? *J Intern Med* 2003;253:4-17.
8. de Sanctis JT, Carpenter CF, Sims MD, et al. Culture-negative endocarditis and the use of molecular diagnostics. *Infectious Diseases in Clinical Practice* 2010;18:120-3.
9. Itoh S, Kazumi Y, Abe C, Takahashi M. Heterogeneity of RNA polymerase gene (*rpoB*) sequences of *Mycobacteria gordonae* clinical isolates identified with a DNA probe kit and by conventional methods. *J Clinical Microbiology* 2003;41:1656-63.
10. Measuring Usability: A/B Test Calculator., 2012. (Accessed April 7, 2013, at <http://www.measuringusability.com/ab-calc.php#comments>.)
11. MedCalc Software. (Accessed October 29, 2013, at [http://www.medcalc.org/calc/odds\\_ratio.php](http://www.medcalc.org/calc/odds_ratio.php).)
12. Asking J GJ, Eklund A, Hillerdal G, Akbom A. Increased risk for cancer following sarcoidosis. *Am J Respir Crit Care Med* 1999;160.
13. Social Security Death Index. 2013. (Accessed April 7, 2013, at <http://www.genealogybank.com/gbnk/ssdi/?kbid=9064&m=9>.)
14. Li N, Bajoghi A, Kubba A, Bhawan J. Identification of mycobacterial DNA in cutaneous lesions of sarcoidosis. *J Cutaneous Pathology* 1999;26:271-8.
15. Eishi Y, Suga M, Kobayashi D, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. *J Clinical Microbiology* 2002;40:198-204.
16. Drake WP, Pei Z, Pride DT, Collins RD, Cover TL, Blaser MJ. Molecular analysis of sarcoidosis tissues for *Mycobacterium* species DNA. *Emerging Infectious Diseases* 2002;8:1334-41.
17. Ichikawa H, Kataoka M, Hiramatsu J, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Disease* 2008;25:15-20.
18. Ishige I, Takemura T, Kobayashi L, et al. *Propionibacterium acnes* is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Disease* 2005;22:33-42.
19. Fenollar F, Didier R. Culture of *Tropheryma whippelii* from human samples: a 3-year experience (1999-2002). *J Clin Microbiol* 2003;41:3816-22.

20. Rubin EJ. The granuloma in tuberculosis--Friend or foe? *New England Journal of Medicine* 2009;360:2471-3.
21. Iannuzzi MC, J.R. F. Sarcoidosis, clinical presentation, immunopathogenesis and therapeutics. *Journal of the American Medical Association* 2011;305:391-9.
22. McFadden JJ, Fidler HM. Mycobacteria as possible causes of sarcoidosis and Crohn's disease. *Journal of Applied Bacteriology* 1996;81:47S-52S.
23. Motiwala AS, Li L, Kapur V, Sreevatsan S. Current understanding of the genetic diversity of *Mycobacterium avium* subspecies *paratuberculosis*. *Microbes and Infection* 2006;8:1406-18.
24. Chamberlain W, Borody TJ, Campbell J. Primary treatment of Crohn's disease: combined antibiotics taking center stage. *Expert Reviews in Clinical Immunology* 2011;7:751-60.
25. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. *American Journal of Gastroenterology* 2011;106:661-73.
26. Das K, Seril DN. *Mycobacterium avium* subspecies *paratuberculosis* in Crohn's disease: The puzzle continues. *Journal of Clinical Immunology* 2012;46:627-8.
27. Nicoletti F, Conrad D, Wang A, et al. 16alpha-bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. *Clinical and Experimental Immunology* 2009;158:308-16.
28. Stickney DR, Novelijic Z, Garsd A, Destiche DA, Frincke JM. Safety and efficacy of immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. *Antimicrob Agents Chemotherapy* 2007;51:2639-41.
29. Edelson E. Isoniazid in the treatment of sarcoidosis; a preliminary report. *J Invest Dermatology* 1953;21:71-4.
30. Sahasranaman V, Tucci VT, Vincent AL, Sandin RL, Greene JN. The clinical manifestations, diagnosis and treatment of non-tuberculous mycobacteria infections. *Journal of General Medicine* 2008;20:31-45.
31. Israel HL, Sones M, Harrell D. Ineffectiveness of isoniazid and iproniazid in therapy of sarcoidosis. *Am Review of Tuberculosis* 1953;67:671-3.
32. Holsinger RE, Dalton JE. Isoniazid therapy in cutaneous tuberculosis and sarcoidosis. *Journal of the American Medical Association* 1954;154:475-81.
33. Hoyle C, Dawson J, Mather G. Treatment of pulmonary sarcoidosis with streptomycin and cortisone. *Lancet* 1955;268:638-43.
34. Chatterjee SC, Ghosh JC. Sarcoidosis treated with anti-tuberculous drugs. *Journal of the Indian Medical Association* 1957;29:61-3.
35. James DG, Thomson AD. The course of sarcoidosis and its modification with treatment. *Lancet* 1959;1:1057-61.
36. Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: A review for the pulmonologist. *Chest* 2009;136:583-96.
37. Steen T EJ. Oral minocycline in treatment of cutaneous sarcoidosis. *JAMA Dermatol* 2013;149:758-60.
38. Drake W O-RK, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: A randomized, single-masked, placebo-controlled study. *JAMA Derm* 2013;149.

1  
2  
3 39. Gupta D AR, Aggarwal AN, Jindal SK. Sarcoidosis and tuberculosis: the same disease  
4 with different manifestations or simliar manifestations of different disorders. Curr Opin Pulm  
5 Med 2012;18:506-16.

6  
7 40. Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in  
8 Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial

9 . (Accessed October 29, 2013, at <http://clinicaltrials.gov/show/NCT01245036>.)  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Title: **“BACTERIAL DNA ARE FOUND IN LYMPH NODES OF ALL CHRONICALLY SYMPTOMATIC SARCOIDOSIS PATIENTS MOLECULAR ANALYSIS OF SARCOIDOSIS LYMPH NODES FOR MICROORGANISMS: A CASE-CONTROL STUDY WITH CLINICAL CORRELATES”**

Running Head: Sarcoidosis and Bacteria

Authors: Lary A. Robinson, M.D., FCCP† <lary.robinson@moffitt.org>

Prudence Smith, M.D. \* <prudence.smith@moffitt.org>

Dhruba J. SenGupta, Ph.D.‡ <dsengup@u.washington.edu>

Jennifer L. Prentice, MS, MT, (ASCP)‡ <jprentic@seattlecca.org >

Ramon L. Sandin, M.D.\* <ramon.sandin@moffitt.org>

Institutions: †Center for Infection Research in Cancer, Division of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, USA.

\*Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.

‡Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

Corresponding Author: Lary A. Robinson, M.D., Department of Thoracic Oncology, Moffitt

Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel: (813) 745-6895.

FAX (813) 745-3027. Email <lary.robinson@moffitt.org>

Conflict of Interest: None of the authors has any personal or financial support, nor author involvement with any organization with financial interest in the subject matter.

Research Support: This project was supported by a grant from the W. Paul Hoenle Foundation, Sarasota, Florida 34242, USA

Text Word Count: 2999 Abstract Word Count: 250



1  
2  
3  
4  
5  
6  
7  
8  
9 Keywords: Sarcoidosis; Atypical mycobacteria; Polymerase chain reaction; *Propionibacterium*  
10  
11 *acnes*  
12

13  
14 **ARTICLE SUMMARY:**  
15

16  
17  
18 *ARTICLE FOCUS:*  
19

- 20
- 21 • Sarcoidosis is a common yet incurable, chronic granulomatous disease of  
22 unknown etiology treated with non-specific anti-inflammatory and/or  
23 immunosuppressive drugs.  
24
  - 25 • Persistently symptomatic patients worsen despite treatment with a disabling,  
26 potentially fatal clinical course.  
27
  - 28 • We propose that sarcoidosis results from a chronic granulomatous infection from  
29 a treatable pathogen in certain susceptible individuals, much like granulomatous  
30 ileitis (Crohn's disease) which shows an encouraging response to multi-drug  
31 antimicrobial therapy.  
32  
33  
34  
35  
36

37  
38  
39 *KEY MESSAGES:*  
40

- 41
- 42 • This case-control, retrospective study correlated clinical outcomes with the  
43 presence of detectable bacterial DNA in sarcoidosis lymph nodes versus control  
44 lymph nodes.  
45
  - 46 • The entire group of sarcoidosis patients had significantly more detectable  
47 bacterial DNA than control patient lymph nodes.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17
- However, **all** persistently symptomatic patients have detectable bacterial DNA in their lymph nodes suggesting they have more aggressive sarcoidosis that potentially might benefit from antimicrobial treatment directed against a presumed chronic granulomatous infection.

18  
19

#### STRENGTHS AND LIMITATIONS:

- 20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Although a number of prior studies have demonstrated the consistent presence of bacterial DNA (mostly atypical mycobacteria and *Propionibacterium acnes*) in sarcoidosis tissue, the current study is the first to correlate clinical outcomes with the presence of detectable bacterial DNA, suggesting the most promising candidates for treatment.
  - Nevertheless, the molecular approach to bacterial detection has distinct limitations including possible false-positive results secondary to contaminated PCR reagents, the paraffin imbedding process, or post-embedding handling and processing of the paraffin block. Also the mere physical presence of the bacterial DNA in the lymph nodes does not prove that the disease is caused by the microorganism.
  - Additionally, the number of lymph nodes positive for bacterial DNA may be significantly underestimated because of the tendency of the formalin-fixation and paraffin embedding process to breakdown prokaryotic DNA.

## ABSTRACT

**INTRODUCTION:** Sarcoidosis is an incurable, chronic granulomatous disease primarily involving the lungs and lymph nodes of unknown etiology, treated with non-specific anti-inflammatory/immunosuppressive drugs. Persistently symptomatic patients worsen with a disabling, potentially fatal clinical course. To determine a possible infectious cause, we correlated in a case control study clinical information with the presence of bacterial DNA in sarcoidosis mediastinal lymph nodes compared to control lymph nodes resected during cancer surgery.

**METHODS:** We retrospectively studied formalin-fixed, paraffin-embedded, mediastinal lymph nodes from 30 sarcoidosis patients and 30 control lung cancer patients. Nucleic acids were extracted from nodes, were evaluated by rRNA PCR for bacterial 16S rDNA, and the result was sequenced and compared to a bacterial sequence library. Clinical information was correlated.

**RESULTS:** 11/30 (36.7%) of lymph nodes from sarcoidosis patients had detectable bacterial DNA, significantly more than control patient lymph nodes (2/30, 6.7%),  $p = 0.00516$ . At presentation, 19/30 (63.3%) sarcoidosis patients were symptomatic including all patients with detectable bacterial DNA. Radiographically, there were 18 Stage I and 12 Stage II patients. All Stage II patients were symptomatic and 75% had PCR-detectable bacteria. After a mean follow-up of  $52.8 \pm 32.8$  months, all patients with PCR-detectable bacteria in this series were persistently symptomatic requiring treatment.

**DISCUSSION:** 36.6% of sarcoidosis patients had detectable bacteria DNA on presentation, all of these patients were quite symptomatic, and most were radiographically-advanced stage II patients. These findings suggest bacterial DNA-positive, symptomatic patients have more

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

aggressive sarcoidosis that persists long term, and might benefit from antimicrobial treatment directed against this presumed chronic granulomatous infection.

For peer review only



## INTRODUCTION

Sarcoidosis is a multisystem, granulomatous disease whose etiology is obscure and controversial. Nevertheless, the condition is relatively common with a significantly higher age-adjusted annual incidence in African-Americans (35.5 cases per 100,000) versus Caucasian-Americans (10.9 cases per 100,000). An estimated one million people in the U. S. have this disease. Based on the current U.S. population of 315,556,000, there will be approximately 38,605 new cases of sarcoidosis this year and just over 1000 (2.6%) will die of the illness.<sup>1,2</sup>

The fundamental pathologic abnormality in the disease is the formation of non-caseating epithelioid granulomas, which usually confine poorly soluble foreign material that simply cannot be removed by a single phagocytic cell. The key feature in sarcoidosis is activated CD4+ T cells which differentiate into type 1 helper T cells (Th1), secreting interleukin-2 and interferon- $\gamma$ , augmenting macrophage TNF- $\alpha$ , and amplifying the local cellular immune response.<sup>3,4</sup> This granulomatous inflammation interferes with local tissue homeostasis leading to organ impairment.

Since sarcoidosis primarily involves the lungs, eyes and skin, attention has focused on airborne environmental antigens that might trigger this presumed hypersensitivity response with its T cell-mediated cellular immune response.<sup>3</sup> Similar granulomatous responses can be seen from a variety of infectious agents including mycobacteria, parasites (schistosoma), and fungi (coccidiomycosis). Early studies reported associations with non-infective agents including beryllium, zirconium, aluminum, wood-burning stoves, tree pollen, clay soil, talc, insecticides, inorganic particles, and moldy environments, but none of these theoretical causes has endured.<sup>3,5,6</sup> There is also a several-fold increased incidence of sarcoidosis occurring in siblings

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

and parents, as well as a consistent strong association with specific gene products such as class I and class II HLA antigens, which may add to the familial connection.

Although no infectious agent has been cultured directly from sarcoidosis tissues, clinical and immunologic characteristics of the disorder provide the strongest support for a microbial etiology, at least in some patients.<sup>5-7</sup> To explore a possible infectious cause in patients seen at the Moffitt Cancer Center, we correlated the clinical presentation and long-term follow-up of sarcoidosis patients with the presence of bacterial DNA in archived, surgically-resected mediastinal lymph nodes. Results from sarcoidosis nodes were compared to control lymph nodes resected at the time of lung surgery in node-negative, Stage I non-small cell lung cancer patients.

## METHODS

### *Regulatory Oversight*

Tissue and clinical data in this case-control study was obtained after approval by the Moffitt Cancer Center Scientific Review Committee Protocol MCC #16131 and the University of South Florida IRB Protocol #108656.

### *Study Design*

By searching the Moffitt Cancer Center surgical pathology database between January 1, 2000 and April 1, 2010, we retrospectively identified 30 randomly-chosen patients who were diagnosed with sarcoidosis based on the typical radiographic and clinical presentation, and the histologic finding of non-caseating epithelioid granulomata in lymph nodes obtained sterilely only by mediastinoscopy, to avoid possible microorganism contamination by endoscopic biopsies. Special stains for microorganisms were negative on the specimens. For inclusion in

1  
2  
3  
4  
5  
6  
7  
8  
9 this group, the following criteria were used to make the diagnosis of sarcoidosis: 1) chest  
10 radiograph and chest CT findings of symmetrical mediastinal and hilar adenopathy with or  
11 without reticulonodular infiltrates in the lung fields (see Figure 1); 2) when performed, PET  
12 scans demonstrated glucose avidity in the enlarged lymph nodes (see Figure 2); 3) asymptomatic  
13 presentation or typical symptoms of dyspnea, cough, chest tightness/pain, night sweats, fevers,  
14 fatigue, malaise, skin rash or weight loss; 4) lymph nodes showing histologic features of  
15 confluent, non-caseating granulomata; and 5) any known microorganism causes of granulomata  
16 were excluded by history or culture. All histopathologic specimens were reviewed by one of us  
17 (P.S.) to reconfirm the diagnosis made originally by departmental pathologists at Moffitt.  
18  
19  
20  
21  
22  
23  
24  
25

26 To insure sterile collection, all control specimens were taken from lymph nodes removed  
27 at open thoracotomy by one of us (L.R.) in 30 (1:1 match with cases) randomly-chosen patients  
28 with Stage IA non-small lung cancer. Lymph nodes were selected only from patients with small  
29 peripheral tumors, no obstructive atelectasis, and no evidence of active infection. One of us (P.S.)  
30 reviewed all control lymph node histology to verify there were no metastases, acute  
31 inflammation, or granulomata.  
32  
33  
34  
35  
36  
37  
38

### 39 *Clinical Data*

40 Clinical data on the patient demographics, initial presenting symptoms and objective  
41 findings were extracted from the electronic medical record on all sarcoidosis patients by one of  
42 us (L.R.). Patients were staged using the modified Scadding radiographic staging system: stage 0  
43 normal chest x-ray; stage 1 hilar and mediastinal adenopathy alone; stage 2 adenopathy and  
44 pulmonary infiltrates; stage 3 pulmonary infiltrates alone; and stage 4 pulmonary fibrosis.<sup>4</sup> Long-  
45 term follow-up clinical status and subsequent treatment regimens for all sarcoidosis patients were  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9 obtained from the electronic medical record and telephone calls placed to the patients or their  
10 immediate family.  
11

#### 12 *DNA Extraction*

13  
14  
15  
16 De-identified, formalin-fixed, paraffin-embedded blocks of lymph nodes from sarcoidosis  
17 and control patients were sent to the Departments of Laboratory Medicine and Microbiology at  
18 the University of Washington (Seattle, WA), where investigators were blinded as to the identity  
19 of the specimens. The DNA extraction from paraffin-embedded blocks was performed after  
20 paraffin was removed by incubation in xylene using the Roche HighPure PCR template  
21 purification kit (Roche Diagnostics GmbH, Mannheim, Germany).<sup>8</sup> Several negative patient  
22 samples (unrelated to the present study) were included in each batch to rule out contamination.  
23 Inhibition was ruled out by checking the ability of exogenously added target DNA to be  
24 amplified in the same PCR mix that contained DNA extracted from clinical specimen.  
25 *Mycobacterium tuberculosis* and *Bartonella henselae* have been detected multiple times in the  
26 past using these PCR assays. 16S primers used were broad range for all bacteria. hsp65 and  
27 rpoB were broad range for Mycobacteria spp only. 16S PCR detected non-Mycobacterium  
28 species DNA such as *Propionibacterium acnes*. Mycobacterium sp. DNA were detected by  
29 hsp65 and/or rpoB primers. Primers used for amplification were also used for amplicon  
30 sequencing. The PCR amplicon was directly sequenced; no cloning was performed. Mixed  
31 infection was not detected in this set of specimens. For alignment, BLASTN was used.  
32 Identification was based on exact match on all cases. No sequence that could not be linked to a  
33 microbe was detected.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

*P. acnes* was detected by 16S primers and *M. avium* was detected by hsp65 primers.

Formatted: Font: Italic

*Mycobacterium avium* was detected and identified by sequence analysis.<sup>7, 8</sup>

Formatted: Font: Italic

Formatted: Font: Italic

*PCR Analysis for 16S ribosomal DNA, Heat Shock Protein 65(hsp65), RNA polymerase subunit (rpoB)*

The 16S gene fragment was amplified as previously described.<sup>8</sup> The hsp65 gene was amplified using TB11 and TB12 primers, and the RNA polymerase subunit gene (rpoB) was amplified using MF and MR primers.<sup>9</sup> The amplified products were then sequenced using the Big Dye Sequencing kit (Applied Biosystems, Foster City, CA) using the vendor's recommended protocol. The sequences of two strands were assembled into doubled-stranded contig using Sequencher software (Gene Codes, Ann Arbor, MI). The final sequences were used to search the National Center for Biotechnology Information (National Institutes of Health) database using BLAST (Basic Local Alignment Search Tool) to identify the amplified DNA.

#### *Quantitative Variables*

The primary variable to be compared between the sarcoidosis and controls patients is the number of patients in each group with bacterial DNA found in lymph nodes. The N-1 Two Proportion test for comparing independent proportions for small sample sizes is used to compare the results between the two groups.<sup>10</sup> Additionally, odds ratios with 95% confidence intervals were calculated.<sup>11</sup> All numerical data is expressed as the mean  $\pm$  standard deviation.



## RESULTS

Demographic and clinical characteristics of the 30 sarcoidosis study patients are found in Table 1.

### *Demographics*

Patient ages are: mean  $52.5 \pm 12.3$  years (median 53 years, range 30-75 years). The male:female ratio is 14:16. The ethnicity: Caucasian 73.3% (22), African-American 16.7% (5), and Hispanic 10% (3). Most patients were overweight: mean BMI  $31.4 \pm 6.9$ , median 28.5, range 18.8-47.3.

### *Clinical Presentation*

At the time of initial presentation, 19 of 30 patients (63.3%) were symptomatic, usually with multiple symptoms. Of these 19 patients, the duration of symptoms before diagnosis was a mean  $22.1 \pm 30.0$  months (median 12 months, range 1-120 months). The most common symptoms were night sweats 9 (30.0%); dyspnea 8 (26.7%); chest pain 7 (23.3%); chest tightness 5 (16.7%); fevers 3 (10.0%); fatigue 3 (10%); skin rash 2 (6.7%); and stomach ulcer 2 (6.7%). Other symptoms present in at least one patient include: dyspepsia, dysphagia, diarrhea,

Table 1. Sarcoidosis Patient Results

No.	Age/ Sex	Race	X-ray Stage	Pack-Year Smoking	Prior Cancer	Chemo	PCR Result on Lymph Nodes	Initial Symptoms (year)	Follow- up (mo.)	Current Status (Long-Term)
1	41/F	AA	I	7	Uterine	No	<i>Mycobacteria chelonae</i>	Yes (2009)	36	Sympt., alive
2	63/F	C	II	20	Breast	Yes	<i>Mycobacteria chelonae</i>	Yes (2008)	12	Sympt., deceased from COPD 2009
3	64/F	C	II	None	None	No	<i>Mycobacteria mucogenicum</i>	Yes (2008)	41	Sympt., alive
4	43/M	C	I	None	Melanoma	No	Negative	No (2009)	31	Asympt., alive
5	61/F	C	I	None	Synovial cell sarcoma	Yes	Negative	No (2009)	23	Asympt.; new endomet. ca, alive
6	39/M	C	II	5	None	No	<i>Propri<i>o</i>bacterium acnes</i>	Yes (2008)	35	Sympt., alive
7	58/M	C	I	3	Tonsil cancer	Yes	<i>Corynebacterium propinquum</i>	Yes (2006)	65	Sympt.; tonsil ca. relapse, alive
8	54/M	C	II	None	None	No	<i>Propri<i>o</i>bacterium acnes</i>	Yes (2006)	60	Sympt., alive
9	52/F	AA	I	6	None	No	Negative	Yes (2007)	58	Sympt., alive
10	53/F	C	I	5	Melanoma	Yes	Negative	No (2007)	53	Asympt., alive
11	34/M	AA	II	None	None	No	<i>Propri<i>o</i>bacterium acnes</i>	Yes (2007)	53	Sympt., alive
12	40/M	C	I	Cigars	None	No	Negative	Yes (2007)	36	Sympt., alive
13	49/M	AA	II	None	None	No	<i>Duganella zoogloeoides</i>	Yes (2010)	Lost	Unknown, alive
14	57/F	AA	II	5	Breast	Yes	<i>Propri<i>o</i>bacterium acnes</i>	Yes (2000)	136	Sympt; breast ca. relapse; polymyalgia rheumatica; Hashimoto's thyroiditis, alive
15	67/M	C	I	None	None	No	Negative	No (2001)	Lost	Unknown, alive
16	30/M	H	I	None	None	No	Negative	No (2001)	Lost	Unknown, alive
17	75/F	C	I	None	Ovarian	Yes	Negative	No (2002)	36	Asymptomatic, deceased from ca., 2005
18	67/F	C	I	50	Liposarcom a	No	Negative	No (2003)	106	Sympt., alive
19	60/F	C	I	None	Nerve sheath tumor	No	Negative	No (2003)	60	Asympt., deceased unknown cause 2008
20	41/F	C	I	None	None	No	Negative	No (2005)	78	Asympt., alive
21	50/F	C	I	None	None	No	Negative	Yes (2005)	73	Asympt., alive
22	48/F	C	I	None	Breast	Yes	<i>Propri<i>o</i>bacterium acnes</i>	Yes (2003)	24	Sympt.; deceased from ca. 2005
23	41/F	C	II	None	Adrenal ca; melanoma	Yes	Negative	Yes (2006)	4	Deceased from ca. 2007
24	35/M	H	I	2.5	None	No	Negative	Yes (2006)	24	Asympt., alive
25	32/M	C	I	1.0	None	No	Negative	No (2006)	Lost	Unknown, alive
26	37/M	C	II	15	Hodgkin's disease	Yes	<i>Propri<i>o</i>bacterium acnes</i>	Yes (2007)	66	Sympt., alive
27	51/F	AA	II	None	None	No	Negative	No (2007)	64	Sympt; (mildly), alive
28	56/F	C	II	None	Colon ca.	Yes	Negative	No (2008)	Lost	Unknown, alive
29	33/M	C	I	5	Melanoma	No	Negative	No (2009)	38	Asympt., alive
30	52/F	H	II	1	Uterine	No	Negative	Yes (2002)	48	Asympt., alive

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 abbreviations: AA = African-American; Asympt. = asymptomatic; C = Caucasian; Ca. = cancer;  
Chemo = chemotherapy; COPD = chronic obstructive pulmonary disease; H = Hispanic; Sympt. =  
symptomatic. All patients positive on PCR for microorganism DNA in lymph nodes are shown in bold  
type.

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9 constipation, kidney stones, joint and muscle pains, orthopnea, nose and mouth skin lesions,  
10 intermittent bronchospasm, malaise, and weight loss.

11  
12 Co-morbidities: asthma 2 (6.7%); coronary artery disease 2 (6.7%); diabetes mellitus 4  
13 (13.3%); hypertension 5 (16.6), and one each of gout, hypothyroidism, eczema, fibromyalgia,  
14 and Crohn's disease. Malignancies were extremely common with over half (53.3%) having a  
15 current or prior tumor, [a finding noted previously by others](#).<sup>12</sup> The malignancies prior to or at the  
16 time of presentation are: breast 3, melanoma 3, uterine 2, sarcomas 3, tonsil 1, ovary 1, adrenal 1,  
17 colon 1, and Hodgkin's lymphoma 1.  
18  
19  
20  
21  
22  
23  
24

#### 25 *Radiographic Studies*

26  
27 Chest CT was performed on all 30 patients and all had symmetrical mediastinal and hilar  
28 adenopathy. Four of 30 (13.3%) had obvious abdominal adenopathy. Lung nodules were present  
29 in 12 patients (40.0%) and were radiographic Stage II sarcoidosis. The other 18 patients (60.0%)  
30 had Stage I disease. All 12 Stage II patients were symptomatic. PET/CT scans were done in 25  
31 of 30 sarcoidosis patients. All demonstrated glucose avidity in the enlarged mediastinal and hilar  
32 nodes (see Figure 2 for typical example), and glucose avidity was seen in the abnormal  
33 abdominal nodes in the 4 patients with radiographic adenopathy below the diaphragm.  
34  
35  
36  
37  
38  
39  
40  
41  
42

#### 43 *Laboratory Results*

44  
45 Twelve of 30 patients had lymph node tissue sent at the time of mediastinoscopy for  
46 aerobic, fungal and mycobacterial cultures. All cultures showed no growth after six weeks  
47 incubation.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Bacterial DNA Detected by PCR*

Eleven of 30 lymph nodes (36.7%) in sarcoidosis patients had bacterial DNA present by PCR. Only 2 of 30 (6.7%) control patients were found to have bacterial DNA in their lymph nodes. The microorganisms present in each group are shown in Table 2. There are significantly more sarcoidosis patient lymph nodes positive for microorganism DNA than control lymph nodes: 11/30 versus 2/30,  $p = 0.00516$  (2-tailed  $p$ -value); the odds ratio is 8.1053 with 95% confidence intervals 1.6115-40.7675,  $p = 0.0111$ .

Formatted: Font: Italic

All sarcoidosis patients with detectable bacterial DNA in lymph nodes (36.7%) were symptomatic at presentation. Additionally, 73% (8/11) of bacterial DNA-positive sarcoidosis patients were both symptomatic at presentation and had radiographic Stage II disease.

### *Long-Term Follow-up*

Long-term follow-up was complete in 25 of 30 (83.3%) of sarcoidosis patients, for a mean follow-up of  $50.4 \pm 28.2$  months (median 48 months, range 4 -132 months). Five of these patients are deceased: 3 from cancers, 1 from chronic obstructive pulmonary disease, and one from unknown causes. The other five patients lost to direct follow-up are still living based on information obtained from the Social Security Death Index.<sup>13</sup>

Of the 10 sarcoidosis patients with bacterial DNA found in their lymph nodes in this series in whom long-term follow-up was available, **all** were symptomatic at follow-up a mean  $52.8 \pm 32.4$  months (median 47 months, range 12-136 months). The one additional bacterial DNA-positive patient was lost to follow-up.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11 **Table 2. Bacterial DNA detected by PCR**

12  
13 **Sarcoidosis (11/30)**

14 *Propionibacterium acnes*: 7

15 *Mycobacterium*

16 *chelonae*: 2

17 *mucogenicum*: 1

18 *Duganella zoolooides*: 1

19 *Corynebacterium propinquum*: 1

20  
21 **Control (2/30)**

22 *Mycobacterium avium*: 1

23 *Propionibacterium acnes*: 1

## DISCUSSION

The objectives of this case-control study were two-fold: a) evaluate sterilely-resected lymph nodes in documented sarcoidosis patients for the presence of bacterial DNA by molecular methods and b) correlate the results with clinical characteristics of the patients.

### *Bacterial DNA*

As expected, our molecular testing using PCR demonstrated that over one-third of sarcoidosis patients (36.7%) had evidence of bacterial DNA in the nodes, indicating either past or current involvement with these microorganisms. This percentage of bacterial DNA-positive specimens falls in the range found in numerous prior published studies from the last two decades (using various methodologies), which range from 26%-80% positive (Table 3<sup>5,7,14-17</sup>). Furthermore, atypical mycobacteria and *Propionibacterium acnes* represented almost all DNA identified, also consistent with the findings of the multiple prior studies (Table 3). Additionally identified were one skin and mucous membrane organism (*Corynebacterium propinquum*), and one aerobic Gram negative bacillus (*Duganella zoogloeoidea*) that is usually found in aqueous environments. Interestingly, the latter patient (no. 13) with *Duganella zoogloeoidea* was an asbestos technician originally from tropical Haiti. As a disclaimer, just the finding of DNA from a microorganism in lymph nodes does not tell us whether the viable organism is present or whether it caused the granulomatous reaction.

Similar to prior published studies summarized in Table 3, significantly less (only 2 of 30 or 6.7%,  $p = 0.00516$ ) of control lymph nodes resected at the time of lung cancer surgery showed

evidence of bacterial DNA (*Mycobacterium avium intracellulare* and *Propionibacterium acnes*).

This difference strongly suggests that the demonstration of bacterial DNA in sarcoidosis lymph

**Table 3. Selected studies of DNA of infectious agents found in sarcoidosis tissues**

Author/Year	Sarcoid Tissue (No. patients)	Technique	Organisms (%)	Control No. (% organisms)
Li, 1999 <sup>11</sup>	Skin (20)	PCR (restriction enzyme pattern)	<i>Mycobacteria</i> (2 <i>tuberculosis</i> , 14 other <i>mycobacteria</i> . 80% total positive)	20 Normals (0% organisms)
Du Bois, 2003 <sup>7</sup> (Review of pre-1999 studies)	Lymph nodes (12 studies with 295 patients)	PCR (various methods)	<i>Mycobacterium</i> sp. (34%)	Various
Eishi, 2002 <sup>12</sup> (5 center study)	Lymph nodes (108)	Quantitative real-time PCR	<i>P. acnes</i> (72%) <i>P. granulosum</i> (55%) <i>M. tuberculosis</i> (4%) <i>E. coli</i> (2%)	86 Normals (29% <i>P. acnes</i> , 12% <i>P. granulosum</i> , 2% <i>M.</i> <i>tuberculosis</i> )
Drake, 2002 <sup>13</sup>	Lymph nodes (25)	Nested PCR	<i>Mycobacterium</i> sp. (60%)	25 Normals (0%)
Gupta, 2007 <sup>5</sup> (metanalysis)	Various (31 studies with 874 patients)	PCR (various methods)	<i>Mycobacterium</i> sp. (26%)	745 Controls (3%)
Ichikama, 2008 <sup>14</sup>	Bronchoalveolar lavage (42)	Quantitative PCR	<i>Propionibacterium</i> sp. (3X higher genome levels vs. controls)	30 Controls (low levels same genome)



1  
2  
3  
4  
5  
6  
7  
8  
9 nodes is a real finding in our study (and in over 35 prior published studies) and they are not just  
10 processing contaminants, therefore pointing to microorganisms as potential contributors to the  
11 genesis of this disease. In addition, *Propionibacterium acnes* DNA was found in only 1 of 30  
12 (3.3%) control lymph nodes in our study, in stark contrast to Ishige and associates in Japan who  
13 reported this microorganism is an ubiquitous pulmonary lymph node commensal found in 8 of 11  
14 (72.7%) non-sarcoid patients in their study.<sup>18</sup> Such a very high positive result in their study is  
15 likely due to either geographical/ethnic/racial differences or potential contamination in processing.  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 *Clinical Characteristics*

25 Perhaps the most intriguing findings came from correlation of the PCR findings with the  
26 clinical information. All patients with lymph nodes containing bacteria DNA on presentation  
27 were also highly symptomatic and 75% of them had the poorer-prognosis radiographic stage II  
28 findings. Moreover, after a median 4 years follow-up, **all** bacterial DNA-positive patients were  
29 *still* highly symptomatic. This striking correlation strongly suggests that demonstration of  
30 bacterial DNA by PCR in lymph nodes on initial presentation is an adverse prognostic factor and  
31 makes it unlikely that these patients will have a spontaneous remission.  
32  
33  
34  
35  
36  
37  
38

39 Indeed, if infection with one of these microorganisms triggers an exuberant  
40 granulomatous immune response, the 50-80% of patients who usually have a spontaneous  
41 remission<sup>1</sup> likely clear the offending organism and the immune reaction subsides. We postulate  
42 that those patients who have persisting symptomatic disease, likely continue to harbor the  
43 microorganism which perpetuates the vigorous, destructive immune response, and as well as  
44 permit the microorganism to travel elsewhere to other organs to create distant granulomatous  
45 inflammation.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Font: Bold

### Limitations of Study

Many pathogenic microorganisms such as *Mycobacterium leprae* (leprosy) ~~*Tropheryma whippelii* (Whipple's disease)~~ or coronaviruses (severe acute respiratory syndrome) cannot be grown directly in culture or they are very slow growing ~~or fastidious or difficult to culture~~ such as ~~*Tropheryma whippelii* (Whipple's disease) *Mycobacterium leprae* (leprosy)~~.<sup>5,19</sup> In these instances, detection and identification rely on molecular mechanisms such PCR used in this study. Nevertheless, the molecular approach has distinct limitations including possible false-positive results secondary to contaminated PCR reagents, the paraffin imbedding process, or post-embedding handling and processing of the paraffin block. However in our study, thirty control lymph nodes were processed in an identical manner and bacterial DNA was detected in only 2/30 (6.6%), significantly less than the sarcoidosis nodes (36.7%,  $p = 0.00516$ ), suggesting that contamination is unlikely to account for the findings.

Another obvious limitation in interpreting the results of this and other prior molecular studies relates to colonization versus causation. Just the finding of microbial DNA in the nodes does not prove that the organism is actively involved in the pathogenesis of the disease. The microorganism may just be a commensal or theoretically it might even be attracted to the area of granulomatous inflammation. Nevertheless, the marked difference in the percentage of microbial DNA-positive nodes in sarcoidosis versus control patients is certainly suggestive of disease causation by the microorganisms.

Additionally, the number of lymph nodes positive for bacterial DNA may be significantly underestimated because of the tendency of the formalin-fixation and paraffin embedding process to breakdown prokaryotic DNA. ~~Also, over~~Over time other investigators have found degradation

1  
2  
3  
4  
5  
6  
7  
8  
9 of the prokaryotic bacteria DNA (especially mycobacteria) with aging of the paraffin-embedded  
10 specimens.<sup>16</sup> Of note, the only 3 sarcoidosis lymph nodes positive for mycobacteria in our study  
11 were less than 3 years old when evaluated by PCR. Had we used fresh lymph node tissue like  
12 Drake and associates<sup>16</sup> who found 60% PCR positive for mycobacteria species, there may have  
13 been a much higher rate of positive bacterial DNA results (particularly mycobacteria) in our  
14 study.  
15  
16  
17  
18  
19

#### 20 21 22 23 24 *Implications of the Study*

25 Sarcoidosis is a granulomatous disease primarily involving the lungs, lymph nodes and  
26 other organs that appears to be the result of an exuberant T cell and macrophage immunologic  
27 response to the continued presentation of a poorly degradable antigen. Numerous non-infective  
28 agents have been implicated based on epidemiologic basis but none have stood up to scrutiny.<sup>1,3,5</sup>  
29 The focus over the last two decades has been on infective agents that might trigger sarcoidosis,  
30 with the strongest suspects found in the mycobacteria family and the common commensal  
31 *Propionibacterium acnes*. And like classical tuberculosis where up to 90% of people infected  
32 with *Mycobacterium tuberculosis* remain in remission without treatment,<sup>20</sup> sarcoidosis also has a  
33 65-80% spontaneous remission rate without treatment.<sup>1</sup> One may speculate that similar to  
34 tuberculosis, the immune system, after its initial response to a triggering microorganism, is  
35 successful in eradicating the agent and the immune response subsides. Then in the 20% or so  
36 with persistent and progressive sarcoidosis, the organism remains viable and perpetuates the  
37 destructive immune response.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Symptomatic sarcoidosis is usually treated with various anti-inflammatory and immunosuppressive agents such as corticosteroids, methotrexate and TNF-inhibitors (biologics).<sup>21</sup> The similarities in immunologic abnormalities and treatment to another debilitating granulomatous disease, Crohn's disease, are striking.<sup>22</sup> Granulomatous ileitis (Crohn's) has been suspected by many investigators to be the result of a chronic infection with the obligate intracellular microorganism *Mycobacterium ~~avian~~ avium* subspecies *paratuberculosis* (MAP), that is known to cause a granulomatous ileitis in cattle and other ruminants called Johne's disease.<sup>23</sup> Although the classical treatment of Crohn's disease has been with immunosuppressive agents just like with sarcoidosis, many recent studies suggest a much more effective treatment with less side effects may be a triple antibiotic regimen geared toward the putative triggering agent MAP.<sup>24-26</sup> In fact, many in the field suspect that this intracellular organism (MAP) that resides in the macrophage impairs the normal autophagy that would usually eradicate the organism.<sup>24</sup> Agents that enhance autophagy such as 16 $\alpha$ -bromoepiandrosterone,<sup>27,28</sup> currently in human trials, may prove effective along with antibiotics in Crohn's disease.<sup>24</sup>

Can some antibacterial/anti-mycobacterial regimen such as that used in Crohn's disease alter the natural history of sarcoidosis in chronically symptomatic patients? Sixty years ago a number of small trials using classical anti-tuberculous drugs (isoniazide, streptomycin, or cortisone) were published with discouraging results.<sup>29</sup> However, atypical mycobacteria (rather than *M. tuberculosis*) that are more likely to be one of the etiologic agents in sarcoidosis, are almost all resistant to the standard anti-tuberculosis agents such as isoniazid.<sup>30-35</sup> And if other organisms such as *Propionibacterium acnes* or perhaps cell-wall deficient (L-forms) bacteria trigger and perpetuate sarcoidosis in some individuals, then the standard anti-tuberculous drugs would also be ineffective.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The tetracycline derivatives (minocycline and doxycycline), as well as the anti-malarial drug chloroquine have been shown to be quite effective in treating cutaneous sarcoidosis.<sup>36</sup>

Minocycline can produce complete responses in up two-thirds of cases, although it is debated whether this is an anti-microbial effect or an immunomodulating effect.<sup>37</sup>

Attention has recently turned to randomized sarcoidosis treatment trials with various anti-microbial agents. W. P. Drake and associates just published positive results of the first randomized trial (NCT01074554) of an anti-microbial regimen (directed at atypical mycobacteria) in the United States using oral levofloxacin, ethambutol, azithromycin and rifampin (CLEAR) to treat 30 patients with cutaneous sarcoidosis, with quite significant reductions in cutaneous lesion size.<sup>38</sup> In 2012, D. Gupta and associates in their comprehensive review of sarcoidosis and its similarities to tuberculosis presents a convincing case for anti-tuberculous treatment of sarcoidosis.<sup>39</sup> D. Gupta is also the principal investigator in an ongoing clinical trial in India using more standard anti-tuberculous therapy “Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial” (ClinicalTrials.gov Identifier: NCT01245036).<sup>40</sup> The results of this trial in India with its high burden of tuberculosis will be available next year, though the drug regimen used may not be as effective in countries with a low tuberculosis burden. If indeed sarcoidosis arises from an abnormal immunologic response to a microorganism(s), the patient’s geographical location may dictate which microorganism is involved and what anti-microbial regimen will be most effective.

The tetracycline derivatives (minocycline and doxycycline), as well as the anti-malarial drug chloroquine have been shown to be quite effective in treating cutaneous sarcoidosis.<sup>36</sup>

Formatted: Indent: First line: 0.5"

Formatted: Font: Times New Roman, 12 pt

~~Minoocycline can produce complete responses in up two thirds of cases, although it is debated whether this is an anti microbial effect or an immunomodulating effect.~~

### Conclusions

Over the last three decades or more, numerous studies have examined every aspect of sarcoidosis including its dysfunctional immune response. The primary therapy is immune suppression in various forms but this treats only symptoms and does not seem to alter the natural history of the disease.<sup>4,21</sup> Dozens of studies (Table 3) have repeatedly demonstrated evidence of microorganisms in 30-80% of sarcoidosis tissues, mostly various mycobacteria and *Propionibacterium acnes*, and more of these molecular studies is not likely warranted.

Perhaps we should follow the lead of the Crohn's disease gastroenterologists<sup>24,25</sup> and proceed with a therapeutic clinical trial using a regimen of multiple antibiotics in persistently-symptomatic, advanced stage sarcoidosis patients. Indeed, if there is a persistent, viable microorganism infection causing the continuing or progressive debilitating symptoms and organ failure, antibiotics might favorably impact the course of this disease.

### FIGURE LEGENDS

**Figure 1.** Contrast-enhanced computed chest tomography at 2 different axial levels showing typical symmetrical hilar and mediastinal adenopathy.

**Figure 2.** PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph nodes (arrows).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ACKNOWLEDGEMENTS

**Author contributorship:** Dr. Robinson had full access to all of the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.

*Dr. Robinson:* Contributed to the conception, hypotheses delineation and design of the study; data acquisition, analysis and interpretation; and writing and revision of the article prior to submission.

*Dr. Smith:* Contributed to the conception, hypothesis delineation, and design of the study; data acquisition, analysis and interpretation; and revision of the article prior to publication.

*Dr. SenGupta:* Contributed to the data acquisition, analysis and interpretation; and revision of the article prior to publication.

*Ms. Prentice:* Contributed to the data acquisition, analysis and interpretation.

*Dr. Sandin:* Contributed to the conception, hypothesis delineation, and design of the study; and revision of the article prior to publication.

**Data Sharing:** There is no additional data available.

**Financial/nonfinancial disclosures:** The authors report that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

**Role of sponsors:**

1  
2  
3  
4  
5  
6  
7  
8  
9 The material is the result of work supported with resources and use of facilities at the  
10 Moffitt Cancer Center (Drs. Robinson, Smith and Sandin) and the University of Washington (Dr.  
11 SenGupta and Ms. Prentice).  
12

13  
14 Bacteria were identified by the Molecular Microbiology Laboratory at the University of  
15 Washington Medical Center. <<http://depts.washington.edu/molmicdx/>>.  
16  
17

18 The views expressed herein do not necessarily represent the views of the funding agency  
19 (The Hoenle Foundation), the Moffitt Cancer Center or the University of Washington.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. American Thoracic Society. Statement on sarcoidosis. *Am J Respir Crit Care Med* 1999;160:736-55.
2. Rybicki BA, Maliarik MJ, Major M, Popovich JJ, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. *Semin Respir Infect* 1998;13:166-73.
3. Iannuzzi MC, Brybicki BA, Teirstein AS. Sarcoidosis. *New Engl J Medicine* 2007;357:2153-65.
4. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. *Am J Respir Crit Care Med* 2011;183:573-81.
5. Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a metanalysis. *European Respiratory Journal* 2007;30:508-16.
6. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, et al. A case control etiologic study of sarcoidosis. *Am J Respir Crit Care Medicine* 2004;170:1324-30.
7. DuBois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? *J Intern Med* 2003;203:4-17.
8. de Sanctis JT, Carpenter CF, Sims MD, et al. Culture-negative endocarditis and the use of molecular diagnostics. *Infectious Diseases in Clinical Practice* 2010;18:120-3.
9. Itoh S, Kazumi Y, Abe C, Takahashi M. Heterogeneity of RNA polymerase gene (*rpoB*) sequences of *Mycobacteria gordonae* clinical isolates identified with a DNA probe kit and by conventional methods. *J Clinical Microbiology* 2003;41:1656-63.
10. Measuring Usability: A/B Test Calculator., 2012. (Accessed April 7, 2013, at <http://www.measuringusability.com/ab-calc.php#comments>.)
11. MedCalc Software. (Accessed October 29, 2013, at [http://www.medcalc.org/calc/odds\\_ratio.php](http://www.medcalc.org/calc/odds_ratio.php).)
12. Asking J GJ, Eklund A, Hillerdal G, Akbom A. Increased risk for cancer following sarcoidosis. *Am J Respir Crit Care Med* 1999;160.
13. Social Security Death Index. 2013. (Accessed April 7, 2013, at <http://www.genealogybank.com/gbnk/ssdi/?kbid=9064&m=9>.)
14. Li N, Bajoghi A, Kubba A, Bhawan J. Identification of mycobacterial DNA in cutaneous lesions of sarcoidosis. *J Cutaneous Pathology* 1999;26:271-8.
15. Eishi Y, Suga M, Kobayashi D, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. *J Clinical Microbiology* 2002;40:198-204.
16. Drake WP, Pei Z, Pride DT, Collins RD, Cover TL, Blaser MJ. Molecular analysis of sarcoidosis tissues for *Mycobacterium* species DNA. *Emerging Infectious Diseases* 2002;8:1334-41.
17. Ichikawa H, Kataoka M, Hiramatsu J, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Disease* 2008;25:15-20.
18. Ishige I, Takemura T, Kobayashi L, et al. *Propionibacterium acnes* is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Disease* 2005;22:33-42.
19. Fenollar F, Didier R. Culture of *Tropheryma whippelii* from human samples: a 3-year experience (1999-2002). *J Clin Microbiol* 2003;41:3816-22.

20. Rubin EJ. The granuloma in tuberculosis--Friend or foe? *New England Journal of Medicine* 2009;360:2471-3.
21. Iannuzzi MC, J.R. F. Sarcoidosis, clinical presentation, immunopathogenesis and therapeutics. *Journal of the American Medical Association* 2011;305:391-9.
22. McFadden JJ, Fidler HM. Mycobacteria as possible causes of sarcoidosis and Crohn's disease. *Journal of Applied Bacteriology* 1996;81:47S-52S.
23. Motiwala AS, Li L, Kapur V, Sreevatsan S. Current understanding of the genetic diversity of *Mycobacterium avium* subspecies *paratuberculosis*. *Microbes and Infection* 2006;8:1406-18.
24. Chamberlain W, Borody TJ, Campbell J. Primary treatment of Crohn's disease: combined antibiotics taking center stage. *Expert Reviews in Clinical Immunology* 2011;7:751-60.
25. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. *American Journal of Gastroenterology* 2011;106:661-73.
26. Das K, Seril DN. *Mycobacterium avium* subspecies *paratuberculosis* in Crohn's disease: The puzzle continues. *Journal of Clinical Immunology* 2012;46:627-8.
27. Nicoletti F, Conrad D, Wang A, et al. 16alpha-bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. *Clinical and Experimental Immunology* 2009;158:308-16.
28. Stickney DR, Novelijic Z, Garsd A, Destiche DA, Frincke JM. Safety and efficacy of immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients. *Antimicrob Agents Chemotherapy* 2007;51:2639-41.
29. Edelson E. Isoniazid in the treatment of sarcoidosis; a preliminary report. *J Invest Dermatology* 1953;21:71-4.
30. Sahasranaman V, Tucci VT, Vincent AL, Sandin RL, Greene JN. The clinical manifestations, diagnosis and treatment of non-tuberculous mycobacteria infections. *Journal of General Medicine* 2008;20:31-45.
31. Israel HL, Sones M, Harrell D. Ineffectiveness of isoniazid and iproniazid in therapy of sarcoidosis. *Am Review of Tuberculosis* 1953;67:671-3.
32. Holsinger RE, Dalton JE. Isoniazid therapy in cutaneous tuberculosis and sarcoidosis. *Journal of the American Medical Association* 1954;154:475-81.
33. Hoyle C, Dawson J, Mather G. Treatment of pulmonary sarcoidosis with streptomycin and cortisone. *Lancet* 1955;268:638-43.
34. Chatterjee SC, Ghosh JC. Sarcoidosis treated with anti-tuberculous drugs. *Journal of the Indian Medical Association* 1957;29:61-3.
35. James DG, Thomson AD. The course of sarcoidosis and its modification with treatment. *Lancet* 1959;1:1057-61.
36. Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: A review for the pulmonologist. *Chest* 2009;136:583-96.
37. Steen T EJ. Oral minocycline in treatment of cutaneous sarcoidosis. *JAMA Dermatol* 2013;149:758-60.
38. Drake W O-RK, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: A randomized, single-masked, placebo-controlled study. *JAMA Derm* 2013;149.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

39. Gupta D AR, Aggarwal AN, Jindal SK. Sarcoidosis and tuberculosis: the same disease with different manifestations or simliar manifestations of different disorders. *Curr Opin Pulm Med* 2012;18:506-16.

40. Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcooidosis: a Pilot Randomized Controlled Trial

. (Accessed October 29, 2013, at <http://clinicaltrials.gov/show/NCT01245036>.)

For peer review only



**Fig. 1. Contrast-enhanced computed chest tomography at 2 different axial levels showing typical symmetrical hilar and mediastinal adenopathy**

Contrast-enhanced computed chest tomography at 2 different axial levels showing typical symmetrical hilar and mediastinal adenopathy

225x169mm (72 x 72 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Fig 2. PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph nodes**

PET/CT (coronal view) of symmetrical hypermetabolic mediastinal and hilar lymph nodes (arrows)

225x169mm (72 x 72 DPI)

ew only

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract <a href="#">Page 1, 3, 4</a>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
<b>Introduction</b>			
Background/rationale <a href="#">Pages 5-6</a>	2	Explain the scientific background and rationale for the investigation being reported	
Objectives <a href="#">Pages 5-6</a>	3	State specific objectives, including any pre-specified hypotheses	
<b>Methods</b>			
Study design <a href="#">Page 6</a>	4	Present key elements of study design early in the paper	
Setting <a href="#">Pages 6-7</a>	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants <a href="#">Pages 7-8</a>	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables <a href="#">Pages 6-7</a>	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/ measurement <a href="#">Pages 6-7</a>	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size <a href="#">Not applicable in this case control observational trial</a>	10	Explain how the study size was arrived at	
Quantitative variables <a href="#">Pages 6-7</a>	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods <a href="#">Pages 6, 7, 9</a>	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
<b>Results</b>			
Participants <a href="#">Table 1</a>	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data <a href="#">Table 1</a>	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data <a href="#">Tables 1 and 2</a>	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results <a href="#">Tables 1 and 2</a>	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses <a href="#">Not applicable</a>	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion <a href="#">Discussion section</a></b>			
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability <b>Conclusion section</b>	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding <a href="#">Title page</a>	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

1  
2  
3  
4  
5 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

6 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
7 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
8 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>